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Abstract 
The treatment and prevention of multidrug resistant tuberculosis (MDR TB) is a significant public health 
challenge, particularly in India, which accounts for approximately one quarter of the global burden. First, 
an overview of MDR TB in India and its public sector treatment is provided, including special emphasis on 
the challenges of quality of life during and loss to follow-up from treatment (Chapter 1). Leveraging 
multiple sources of registry data in Pune, India, we identified several risk factors for loss to follow-up and 
mortality during public sector MDR TB treatment. Notably, any history of alcohol use, current treatment 
for extrapulmonary TB and no prior private treatment were associated with increased loss to follow-up. 
Mortality was associated with baseline low body mass index, anemia and any prior loss to follow-up from 
TB treatment (Chapter 2). A prospective cohort of individuals newly diagnosed with MDR TB and drug-
susceptible TB (DS TB) as well as healthy controls testing negative for TB was established in order to 
compare quality of life across all three groups. Baseline quality of life (QOL) was impaired in TB and MDR 
TB patients compared to healthy controls with no significant QOL differences found between individuals 
with DS TB and MDR TB (Chapter 3). In a separate multi-site cross-sectional study, we assessed the 
willingness of household contacts (HHC) of MDR TB index cases to take preventive therapy to reduce their 
risk of TB. Overall, HHC willingness was high and notably associated with high TB-related knowledge, 
comfort telling others about taking preventive therapy and confidence in taking therapy (Chapter 4). This 
dissertation contributes to our understanding of patient-reported and traditional outcomes of public sector 
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The global tuberculosis epidemic and the challenge of drug resistance 
The widespread emergence of increasingly drug resistant forms of tuberculosis (TB) is a substantial 
challenge to current and future TB prevention and care efforts. Despite recent progress in addressing the 
epidemic, TB remains one of the leading causes of mortality globally with an estimated 10.4 million new 
cases and 1.7 million deaths in 2016 alone.1 Multi-drug resistant TB (MDR TB), resistant to at least the two 
most effective 1st-line anti-TB drugs (rifampicin and isoniazid), and rifampicin-resistant TB (RR TB) were 
estimated to have caused 580,000 of these new cases and a disproportionately high number of deaths.1 
While drug susceptible TB (DS TB) is generally curable, treatment outcomes for MDR TB are often dismal 
with only 54% of individuals in 2016 estimated to have had a successful outcome (treatment completion or 
cure).1 MDR TB with additional fluoroquinolone and aminoglycoside resistance (i.e. extensively drug-
resistant TB, XDR TB) often results in even poorer treatment outcomes. The treatment of MDR and XDR 
TB although cost-effective2,3 remains expensive with programmatic costs 10-200 times that of DS TB4,5 
and direct and indirect costs (e.g. lost wages) to patients often exceeding ≥20% of their annual household 
income.6,7 
 
Burden of tuberculosis and drug-resistant tuberculosis in India 
In 2016, India with the world’s second largest population (1.3 billion people) accounted for approximately 
one quarter of the estimated global incidence of TB (2.8 million cases; 211 per 100,000 persons), 33% of 
global TB deaths among human immunodeficiency virus (HIV)-negative persons and 26% of overall global 
TB deaths (435,000; 33 per 100,000 persons).1 Recent household surveys and studies of anti-TB drug sales8 
have been leveraged to improve these estimates; however, they remain limited by the lack of a national TB 
prevalence survey, which is scheduled for 2018 and 2019, as well as poor albeit improving TB notification 
rates from a complex and vast private healthcare sector.1 
 
From the initial rollout of a nationwide DR TB plan in 2007, baseline TB drug sensitivity testing (DST) in 
India was performed only for individuals with a higher risk of resistance (e.g. failures of DS TB regimens 
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and contacts of known pulmonary MDR TB cases).9 With increasing laboratory capacity, these eligibility 
criteria for DST have been expanded over time to include other high-risk groups with a policy of universal 
baseline DST currently being phased in.10 As a result, nationwide prevalence estimates of MDR TB have 
been historically unavailable and instead informed by state-level anti-TB drug resistance surveys from 4 
states.11 Based on these data and public sector recording, there were an estimated 147,000 new MDR TB 
cases in India in 2016 (11 per 100,000 persons),1 also accounting for approximately one quarter of global 
incidence.  
 
The results of the highly anticipated first nationwide prevalence survey of TB drug resistance in India was 
published in early 2018.11 This study was a cluster randomized cross-sectional survey of public sector TB 
diagnostic facilities with the goal of characterizing the prevalence of resistance to 13 anti-TB drugs for 
recently diagnosed individuals. Compared to previous state-level surveys, a similar prevalence of MDR TB 
was identified for new (2.8%) and previously treated individuals (11.6%). However, the identification of 
widespread and diverse resistance to at least one 1st or 2nd line drug (28% new patients; 37% previously 
treated) highlighted the importance of universal DST and personalized TB regimens.11 
 
Public sector TB diagnosis and treatment in India: The Revised National TB Control Programme  
The National TB Programme of India was founded in 1962 and based on a community-oriented approach 
of case finding and self-administered TB treatment at home.12 Over the next three decades, the program 
was plagued by a wide range of challenges, including: inadequate funding, limited passive case finding, 
drug shortages, high rates of loss to follow-up from treatment and the development of anti-TB drug 
resistance. After several national and international review committees, the Revised National TB Control 
Programme (RNTCP) was launched in 1993 on the basis of the internationally recommended Directly 
Observed Treatment - Short Course (DOTS) strategy. Many of the observed challenges of NTP were 
addressed by the pillars of the DOTS strategy: diagnosis by quality ensured sputum smear microscopy, 
treatment by a recently developed and standardized six-month (short course) DS TB regimen, regular 
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supply of anti-TB drugs, standardized recording and monitoring and sustained political and financial 
commitment. Initially piloted in a few districts in India, RNTCP became a national program in 1997 and 
was expanded from 1998 to 2006.13 With many successes, RNTCP continues to provide free of cost public 
sector TB diagnosis, treatment and hospitalization across the country.14,15  
 
Due to the increasing global evidence and consequences of widespread MDR TB in the late 1990s and early 
2000s, the World Health Organization and many key partners created guidelines for the programmatic 
management of drug-resistant TB (PMDT)16 in an attempt to more proactively address the challenge of 
resistance. This approach was introduced in India through RNTCP in 2007 and successfully scaled up 
nationwide by 2013.9,11 
 
MDR TB diagnosis and pre-treatment evaluation in India through PMDT 
In accordance with RNTCP PMDT guidelines,17 initial MDR TB diagnosis is performed using either 
culture-based or rapid molecular assay (line probe assay, LPA; cartridge-based nucleic acid amplification 
testing, CBNAAT) drug sensitivity testing (DST). Accredited DST laboratories include primarily National 
Reference Laboratories and Intermediate Reference Laboratories (IRL) as well as district-level RNTCP 
CBNAAT labs, government medical colleges and some private facilities. Since the rollout of CBNAAT in 
India starting in 2012, DST for presumptive MDR TB has been increasingly decentralized with the step-
wise introduction of CBNAAT machines to high-burden anti-retroviral therapy (ART) centers in 2014, 
high-burden microscopy centers in 2015 and RNTCP district-level laboratories in 2016. Baseline DST 
eligibility criteria have expanded from only individuals failing DS TB treatment prior to 2013 to currently 
all patients diagnosed with TB except for new pulmonary cases without HIV co-infection (Table 1.1).17 As 
RNTCP moves toward universal baseline DST, recent program guidelines have also included DST for other 




MDR TB pre-treatment evaluation and care through RNTCP is coordinated at four progressively 
decentralized administrative levels: Drug-resistant TB Centers (DR TB Centers), District TB Offices 
(DTOs), the sub-district Tuberculosis Units (TUs) and peripheral health institutions (PHIs) or DOT 
centers.17 Individuals diagnosed with MDR TB who plan to initiate public sector treatment are first referred 
for a 3 to 7-day hospitalization for pre-treatment evaluation at a DR TB Center. During this baseline 
assessment, socio-demographic information and clinical history are recorded and relevant imaging (e.g. 
chest radiograph) performed. Baseline laboratory tests include: complete blood count, random blood 
glucose, liver function tests, blood urea, serum creatinine, thyroid stimulating hormone, urinalysis and if 
relevant a pregnancy test. Fasting blood glucose and an oral glucose tolerance test are also performed for 
patients with potential or known diabetes. Patients with unknown HIV status or a negative HIV test that is 
more than 6 months old are referred for HIV counseling and testing at the nearest public sector testing 
center.9,17  
  
At the DR TB Center, all clinical, laboratory and TB diagnostic data are recorded and compiled in patient 
medical records by physicians and staff. A committee of physicians, microbiologists and other clinical 
experts review cases of all individuals eligible for MDR TB treatment and recommend initiation when 
appropriate.9,17 Diagnostic and pre-treatment evaluation data are also abstracted at some DR TB Centers 
onto a single page form by a medical officer and the site’s statistical assistant in preparation for committee 
meetings. After treatment initiation, each individual is assigned an RNTCP PMDT identification number, 
PMDT cards for each administrative level are created for treatment monitoring and patients are registered 
in the PMDT register maintained at the DR TB Center as both a hard copy and also often a soft copy in 
Microsoft Excel. Not all patients are able or willing to present for pre-treatment evaluation at DR TB 
Centers. These individuals, are most often evaluated and initiated on treatment at the district level. Although 
basic patient data is communicated to the DR TB Center to facilitate the assignment of a unique TB 
identification number, complete pre-treatment evaluation data for these individuals is not always readily 
available. 
6 
MDR TB treatment in India through PMDT 
Upon discharge from the DR TB Center, all patients are given a 7-day supply of medication and referred 
to the District TB Office (DTO) corresponding to their place of residence. The DOTS-Plus Supervisor 
(DPS) for each district works with the patient to identify the most convenient location for treatment 
continuation first at the TU-level and then a specific PHI or DOT center. Since the initiation of PMDT in 
India, standardized MDR TB treatments have been administered, consisting of a 6 to 9-month intensive 
phase of 6 drugs (kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol and cycloserine) 
followed by an 18-month continuation phase of 4 drugs (levofloxacin, ethionamide, ethambutol and 
cycloserine) with weight-based dosing. This treatment regimen can be modified to account for 
demonstrated drug intolerance during pre-treatment evaluation or baseline resistance. Monitoring of 
therapy occurs theoretically through direct observation 6 out of 7 days a week for 24-27 months by a 
program-approved DOT provider at a DOT center.9 In practice, however, some patients or their family 
members may be given several days of medication at intervals ranging from a few days to a month.18 For 
pulmonary TB cases, microbiological treatment response is assessed by sputum smear and culture at 3, 4, 
5, 6, 7, 9, 12, 15, 18, 21, and 24 months of treatment with samples analyzed most often at IRLs. Treatment 
response for extrapulmonary TB cases is monitored clinically.  
 
Recording and monitoring of MDR TB treatment in India through PMDT 
MDR TB treatment status is recorded and monitored at each of the four RNTCP PMDT administrative 
levels (Figure 1.1). Separate copies of PMDT treatment cards are maintained at each level for all 
individuals on MDR TB treatment. These treatment cards contain: basic demographic information, HIV 
status, diagnostic DST results, records of the directly observed administration of drugs, follow-up sputum 
culture and chest radiograph results, adverse drug reactions, information on attempts to trace patients during 
treatment interruptions and the final treatment outcome and date. The treatment cards of all levels are 
updated by hand at a series of monthly meetings between the supervisors of each level and the level below. 
For example, DOT Providers at the PHI / DOT center level update treatment cards daily after the 
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administration of drugs. Senior TB Treatment Supervisors (STS) overseeing RNTCP activities at the TU-
level meet with all DOT Providers monthly and update their TU-level treatment cards based on the PHI-
level cards. Similarly, district-level DPSs meet with all STSs at least once per month, and the DPSs in turn 
meet with the DR TB Center’s Data Coordinator monthly.  
 
As a result of the large number of patients and consequently number of treatment cards, PMDT treatment 
registers are also maintained at the district and DR TB Center-levels. These registers provide a summary of 
treatment card information but do not include records of the directly observed administration of drugs, chest 
radiograph results, adverse drug reactions and tracing attempts during treatment interruptions. Data quality 
can be highly variable across all administrative units for patient information in general and specifically for 
data not required for reporting activities or frequently reviewed by supervisors. 
 
Loss to follow-up from MDR TB treatment: a key outcome for patients and programs  
Due to prolonged, costly treatment regimens with less effective and more toxic medications, MDR TB 
treatment is particularly challenging to patients, their families and TB programs. Quality of life is 
substantially impaired by both tuberculosis as well as its treatment through adverse drug events, stigma and 
depression among other mechanisms.19-21 These negative effects, in addition to being important patient 
outcomes on their own, can also lead to poor treatment adherence and loss to follow-up.20,21 Reported public 
sector treatment outcomes in India through RNTCP are poor and similar to global averages: 47% success 
(completion or cure), 20% death and 19% loss to follow-up.10 Loss to follow-up from treatment, most often 
defined for TB as a treatment interruption ≥2 months for any reason has been associated with substantially 
higher mortality,22,23 development of additional drug resistance,24 and the potential for community 





Health-related quality of life during MDR TB treatment 
Traditionally, the focus of TB treatment has been on achieving microbiological cure with less emphasis on 
morbidity and patient-reported outcomes, such as quality of life (QOL). Health-related quality of life is a 
multi-dimensional construct that emphasizes the patient’s perspective and defines health as physical, mental 
and social well-being rather than strictly the absence of illness.25 Despite the well-documented negative 
impacts of TB and TB treatment on quality of life, prior studies have several limitations: study populations 
composed predominantly of young to middle-aged adult males, limited socioeconomic data, a wide range 
of survey instruments utilized, lack of comparison groups and individuals with MDR TB.26-28 
 
Research objectives and conceptual framework 
Strategies aimed at addressing drug-resistant TB have historically focused on preventing acquired drug 
resistance by optimizing DS TB treatment completion and cure rates.9 Recent research has however 
suggested that the primary driver of MDR TB epidemics in high-burden settings may actually be 
transmission, highlighting the fundamental importance of improving MDR TB diagnosis, treatment and 
cure rates.29-31 Achieving the 2015 WHO End TB Strategy32 and the recent Government of India target of 
TB elimination by 202512 will require substantial efforts and funding to continue to improve MDR TB care 
in India. Critical to meeting these targets is a more systematic and granular understanding of the extent and 
severity of TB patient needs and the barriers to treatment retention. The flexible application of this 
knowledge to broad or local implementation challenges will substantially inform both the development of 
treatment support programs and efforts to improve outcomes.33 
 
As patient quality of life and treatment retention are key drivers of treatment success, and loss to follow-up 
an opportunity for intervention, the present research has two primary aims:  
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(1) Examine the timing and risk factors for loss to follow-up among public sector MDR TB patients 
by integrating pre-treatment evaluation, laboratory and treatment data in Western Maharashtra, 
India 
(2) Compare baseline quality of life for newly diagnosed MDR TB and DS TB patients initiating public 
sector treatment to TB-negative healthy controls undergoing sputum microscopy through RNTCP 
in Pune, India  
 
Risk factors of loss to follow-up and challenges during MDR TB treatment were categorized based on 
recent systematic reviews and WHO guideline documents (Figure 1.2).20,34,35 The causal relationships 
between these factors are likely complex and were not investigated. 
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Table 1.1: Change in presumptive MDR TB criteria and availability of cartridge-based nucleic acid 
amplification testing (CBNAAT) during CBNAAT rollout within the Drug-resistant Tuberculosis Center – 




Year Presumptive MDR criteria* CBNAAT
2012 A None
2013 A + B IRL Pune
2014 A B C High-burden ART centers
2015 A B C High-burden microscopy centers
2016 A B C Each district
2017 A B C >1 in some districts + medical colleges
*Criteria A –
• All failures of new TB cases 
• Smear positive previously treated cases who remain smear positive at 4th month onwards 
• All pulmonary TB cases who are contacts of known MDR TB case 
*Criteria B – in addition to Criteria A 
• All smear positive previously treated pulmonary TB cases at diagnosis 
• Any smear positive follow up result in new or previously treated cases 
*Criteria C – in addition to Criteria B 
• All sputum smear negative previously treated pulmonary TB cases at diagnosis, 
• HIV TB co-infected cases at diagnosis 
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Figure 1.1: Administrative levels of programmatic management of drug-resistant tuberculosis in India 
(left), records maintained for pre-treatment evaluation and treatment monitoring (right) as well as the flow 
and timing of treatment data from decentralized to centralized levels in the hierarchy9,17 
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Figure 1.2: Conceptual framework for factors influencing loss to follow-up (LTFU) from public sector 
MDR TB treatment in India 
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Background: Poor treatment outcomes for multidrug-resistant tuberculosis (MDR TB) are a continued 
challenge for patients, clinicians, communities and TB programs. Leveraging programmatic data provides 
an opportunity to identify local challenges and barriers to TB care. In the present analysis, factors associated 
with mortality and loss to follow-up (LTFU) from MDR TB treatment in Western Maharashtra, India were 
examined. 
 
Methods: For this registry analysis, individuals starting public sector MDR TB treatment in 5 districts of 
Western Maharashtra between 2015-2016 were included. LTFU was defined as a treatment interruption ≥2 
months, and mortality defined as death from any cause. Baseline factors associated with LTFU and 
mortality were assessed using cause-specific hazards models. Kaplan-Meier estimates of the cumulative 
incidence of LTFU were corrected for the competing risk of death. The impact of missing values on final 
model parameter estimates was examined by comparing estimates from complete case analyses and after 
multiple imputation to fill in missing values. 
 
Results: In total, 921 individuals on MDR TB treatment were included with 1127 person-years (PY) of 
follow-up after treatment initiation. During follow-up, 130 patients were lost to follow-up and 194 died. 
After adjusting for district, year of treatment registration and baseline covariates, factors significantly 
associated with LTFU after multiple imputation of missing values were history of alcohol use (aHR 1.62, 
95%CI 1.01-2.61), extrapulmonary TB (vs. pulmonary TB, aHR 2.14, 95%CI 1.04-4.41) and any history 
of prior private TB treatment (aHR 0.56, 95%CI 0.34-0.91). Mortality during MDR TB treatment was 
associated with baseline severe underweight (BMI <16 kg/m2; aHR 2.78, 95%CI 1.68-4.59) and moderate 
underweight (<17 & ≥16 kg/m2; aHR 1.94, 95%CI 1.01-3.70) vs. normal BMI or overweight (≥18.5 kg/m2), 
baseline severe anemia (aHR 3.44, 95%CI 1.58-7.52) and moderate anemia (aHR 2.04, 95%CI 1.01-4.12) 
vs. no anemia, any prior LTFU from TB treatment (aHR 2.17, 95%CI 1.56-3.03) and treatment initiation 
in 2016 vs. 2015 (aHR 0.73, 95%CI 0.54-0.99).  
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Conclusion: An understanding of the factors associated with mortality and LTFU from treatment has the 
potential to inform the development and implementation of patient-centered support programs. Efforts to 
address several of the identified risk factors are underway through the public sector TB program in India, 
including: decentralized drug susceptibility testing and integrating TB counseling activities with de-
addiction services.  




Poor treatment outcomes for multidrug-resistant tuberculosis (MDR TB) remain a challenge with 
substantial ramifications for patients, clinicians, communities and TB programs. An understanding of the 
determinants of poor outcomes has the potential to inform efforts to improve TB care and has been 
continually prioritized in national and international TB research agendas.1-3 Significant research has been 
conducted characterizing factors associated with MDR TB treatment outcomes, including: TB resistance 
profiles and treatment characteristics,4-6 directly observed therapy7 and comorbidities.8-10 Although 
significant research on drug susceptible TB treatment outcomes has also been conducted, factors associated 
with poor outcomes may differ from MDR TB due to prior patient treatment experiences as well as a longer, 
more difficult regimen.11 Furthermore, recent studies on MDR TB loss to follow-up and mortality have 
described disparate sets of risk factors in different settings, emphasizing the need to understand local 
context in order to develop effective support programs.12-15  
 
India accounts for approximately one quarter of the global burden of MDR TB.16 Quantitative studies of 
risk factors of loss to follow-up and mortality during MDR TB treatment in India’s large public sector 
program have been predominantly small (~100 patients or less) and often confined to single treatment 
facilities.17-26 Notable retrospective studies of public sector treatment data at district and even national 
levels27-31 have been published primarily for patients initiating treatment between 2007 and 2013. These 
studies have observed that approximately half of treatment loss to follow-up occurred within 6 months of 
initiation, and loss to follow-up was consistently associated with male sex and low BMI as well as in some 
settings migration, provider change during treatment and poor treatment response. Qualitative studies 
examining reported barriers to retention among successfully traced patients lost to follow-up in the Indian 
states of Maharashtra and Gujarat have revealed diverse and multifaceted barriers, including: adverse drug 
effects, stigma, lack of family support, poor relationships with medical providers and competing 
employment demands.32,33 For mortality during MDR TB treatment, prior research has identified 
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associations between higher mortality and low BMI, HIV infection, pulmonary TB and second-line drug 
resistance.29-31,34 
 
This and related prior research, however, has generally had four primary limitations: (1) lack of inclusion 
of likely relevant risk factors (e.g. alcohol and tobacco use),29-31 (2) analysis of composite unfavorable 
treatment outcomes (e.g. death, failure and loss to follow-up) that may have different risk factor patterns if 
outcomes were analyzed individually,24,29 (3) reliance on complete case analyses or a lack of explicit 
description of approaches taken to address missing data30 and (4) survival analyses conducted without 
taking into account competing risks,27,31 such as death for the outcome of loss to follow-up.35,36 Attempting 
to address these limitations, the present research aimed to leverage programmatic public sector MDR TB 
diagnosis, pre-treatment evaluation and treatment data through the DR TB Center – Pune in order to identify 
factors associated with loss to follow-up (LTFU) and mortality during MDR TB treatment. 
 
Methods: 
Study setting:  
Through collaboration with the State TB Office – Maharashtra, the Drug Resistant TB Center – Pune at 
Aundh Chest Hospital (ACH), and the State TB Training and Demonstration Center, Pune (STDC), a 
retrospective cohort of MDR TB patients initiating public sector treatment from 2015 to 2016 was created. 
Established in 2011, the DR TB Center – Pune and STDC coordinate the diagnostic testing, pre-treatment 
evaluation and DR TB treatment for 5 districts in Western Maharashtra, India. Due to the continued 
decentralization of TB care, the districts included within its catchment area have changed over time. 
Kolhapur, Sangli and Sindhudurg Districts were transferred to other centers in 2013, and Raigad District 
was added in July 2015 (Figure 2.1). At present, ACH serves as the DR TB Center for Pune, Solapur, 
Satara, Ahmednagar and Raigad districts that have a combined population greater than 23 million37 and an 
average of approximately 600 individuals initiating public sector MDR TB treatment per year between 2015 




This study included individuals starting public sector MDR TB treatment through RNTCP who registered 
for treatment within the catchment area of the DR TB Center – Pune between January 1, 2015 and December 
31, 2016 with follow-up through April 10, 2018. Exclusion criteria for treatment registrations included: (1) 
XDR TB treatment initiation; (2) previous treatment registration in 2015 and 2016 following transfer out 
or loss to follow-up; (3) missing pre-treatment evaluation data; and, (4) unknown patient treatment status 
and/or treatment outcome date following review of follow-up sputum culture data, PMDT cards, PMDT 
registers and adjudication discussions with district-level DPSs.  
 
Data collection and adjudication: 
For pre-treatment evaluation data, a codebook of potential variables of interest was created based on India’s 
Revised National TB Control Programme (RNTCP) programmatic management of drug-resistant TB 
(PMDT) guidelines38,39 and an initial data review of 2 months of medical records and DR TB Center 
committee forms at ACH. Using this codebook, a standardized Microsoft Excel sheet for data abstraction 
was developed with data validation to minimize entry errors. For all individuals starting treatment at ACH 
between January 1, 2015 and December 31, 2016, relevant data were abstracted from all available case 
papers and DR TB Center committee forms. Any discrepancies between medical records and the committee 
forms were adjudicated with the DR TB Center Statistical Assistant. 
 
For corresponding MDR TB treatment data, an updated version of the soft copy PMDT register was 
obtained from the DR TB Center Statistical Assistant two months prior to study administrative censoring 
on April 10, 2018. All variables were cross-checked with the hard copy PMDT register at the DR TB Center 
and any discrepancies adjudicated with the Statistical Assistant. To obtain the most accurate outcome 
information available, treatment outcomes and dates were also abstracted from DR TB Center PMDT cards. 
Discrepancies, including missingness, between the soft copy PMDT register, hard copy PMDT register and 
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DR TB Center PMDT cards were adjudicated through comparisons with the district-level PMDT registers 
as well as discussions with the DOTS-Plus supervisors (DPS) from each district during their April 10-11, 
2018 monthly data review meeting at ACH. The current treatment status for individuals without any 
recorded treatment outcome was ascertained through discussion with each DPS based on their personal 
knowledge of the individual’s treatment and recent discussions with staff at more decentralized levels. 
Individuals known to be on treatment were administratively censored on April 10, 2018 and a treatment 
outcome of “on treatment” was recorded. Individuals not known to be on treatment or with an unknown 
outcome date were administratively censored as “on treatment” at the last known date of sample collection 
for culture follow-up. 
 
Individual pre-treatment evaluation and MDR TB treatment data were matched using PMDT numbers, 
name, age, sex and district of residence. Data available in both sources (Table 2.1) were compared and 
discrepancies resolved by reviewing both data sources and through discussions with the Statistical 
Assistant. A list of all individuals registered in treatment in 2015 or 2016 but without identified pre-
treatment evaluation data at ACH was compared to records of patients known to have started treatment at 
the district level (i.e. start at district), referred to ACH after pre-treatment evaluation (i.e. refer in) or 
transferred into the DR TB Center – Pune catchment area after public sector treatment initiation elsewhere 
(i.e. transfer in). Remaining individuals with unexplained missing pre-treatment evaluation data were 
discussed with the DR TB Center Statistical Assistant and district DPSs to identify other reasons for 
missingness, including treatment initiation in the outpatient department at ACH or other surrounding 
hospitals. Successful merger of data sources for each individual was verified by manually by comparing 
names and demographic information. Multiple registrations were identified for individuals who were lost 
to follow-up or transferred out and later returned to initiate treatment again. In these cases, the first 





The primary treatment outcomes for this analysis were loss to follow-up and death, which were defined 
according to World Health Organization (WHO) and RNTCP definitions as a treatment interruption ≥2 
months for any reason and death during MDR TB treatment for any reason, respectively.38-40 Other 
treatment outcomes were censored for this analysis and included: cure, treatment completion, treatment 
failure, switch to XDR TB regimen, transfer out and still on treatment. Analyzed baseline risk factors of 
loss to follow-up and mortality during treatment included demographic, clinical, health service and social 
variables routinely collected during pre-treatment evaluation or treatment through RNTCP (Table 2.1). For 
each patient, information about each period of prior TB treatment was abstracted from the medical record 
into the following variables: type of treatment, location (public vs. private), year of initiation, duration and 
outcome. Loss to follow-up from either public or private treatment and any prior treatment in the private 
sector were treated as binary variables. 
 
Baseline clinical factors included: malnutrition, HIV infection, anemia, and diabetes. Nutritional status was 
assessed using body mass index (BMI), which was categorized according to WHO cut-offs: <16 kg/m2 
(severe underweight), 16.0–16.9 kg/m2 (moderate underweight), 17.0–18.49 kg/m2 (mild underweight), 
18.5–24.9 kg/m2 (normal range), ≥25 kg/m2 (overweight).41 The categories of normal and overweight BMI 
were combined due to the small number of individuals in the latter category. HIV status was ascertained 
from HIV test reports at or within 6 months of pre-treatment evaluation or evidence of current anti-retroviral 
treatment in the medical record. Hemoglobin concentrations for the diagnosis of anemia severity were based 
on WHO recommendations,42 which include separate cutoffs for children 6-59 months of age, children 5-
11 years of age, children 12-14 years of age, non-pregnant women 15 years of age and above, pregnant 
women and men 15 years of age and above. Adjustments of hemoglobin concentrations for residential 
elevation above sea level were not required due to the <1000-meter elevation of the study area. Hemoglobin 
adjustments for current smoking status were not possible due to a lack of data. Diabetes was defined as 
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either (1) self-reported diagnosis or diabetes treatment by the patient or (2) fasting plasma glucose 
≥126mg/dL or oral glucose tolerance test at 2 hours of ≥200mg/dL at the time of pre-treatment evaluation.  
 
Health service and social factors included delay in treatment initiation, RNTCP district coordinating 
treatment, year of treatment registration and any history of alcohol or tobacco use. Delay in treatment 
initiation was defined as the days between DST diagnostic sample collection and admission at ACH for 
pre-treatment evaluation. For analysis, delay was categorized as 0-7 days, 8-14 days, 15-30 days and >30 
days. Evidence of either a history of alcohol use or smoking/smokeless tobacco use in the medical record 
were categorized as binary variables. 
 
Statistical analysis: 
Baseline factors associated with loss to follow-up and mortality during public sector MDR TB treatment 
were assessed using survival analysis methods. Person-time contributing to the study was calculated from 
MDR TB treatment initiation to treatment outcomes of interest (loss to follow-up, death) or censoring. 
Individuals were censored on the outcome date for cure, completion, failure, switch to XDR TB treatment 
and transfer out, or on the last known follow-up sputum sample collection date for patients without complete 
outcome information. All individuals still on treatment through April 10, 2018 were administratively 
censored. Covariates of interest were chosen prior to statistical analysis based on literature review and 
conversations with RNTCP staff. Crude loss to follow-up and mortality rates were calculated for levels of 
each covariate included in the analysis. 
 
In survival analysis, the presence of competing events, which preclude the event of interest from occurring, 
may result in informative censoring and biased Kaplan-Meier estimates of the survival function. Two 
approaches have become widely used for these analyses: cause-specific and subdistribution hazards 
models,43 both of which model variations in the standard hazard function used in Cox proportional hazards 
models. The cause-specific hazard is defined as the hazard of experiencing a specific event in the presence 
24 
of competing events. Similar to the standard hazard function, individuals experiencing either the event of 
interest or a competing event are censored and removed from subsequent risk sets. As a result, the modeling 
of covariate effects on cause-specific hazards can be accomplished using Cox proportional hazards models. 
Although, cause-specific hazard ratios (csHR) are a useful measure of association they are not a direct 
measure of association with the risk or cumulative incidence of the event of interest.44,45 The subdistribution 
hazard function redefines the risk sets in a survival analysis by including all individuals who have 
experienced a competing event at a prior time. Although less frequently used, subdistribution hazards 
models (i.e. Fine and Gray models), allow for the estimation of measures of association, the subdistribution 
hazards ratio (sdHR), that are directly related to the risk of the event of interest.44  
 
In the present analysis of factors associated with loss to follow-up from treatment, mortality is a competing 
event. Cumulative incidence curves, produced using Kaplan-Meier estimators corrected for competing 
events if any (Stata –stcompet), were used to visualize the risk of loss to follow-up and mortality during 
treatment. Factors associated with loss to follow-up during MDR TB treatment were examined using both 
univariate and multivariable cause-specific hazards models.  
 
Prior to fitting the final multivariable models, multiple imputation by chained equations (MICE) was used 
to fill in values46 for the following variables: tobacco use (11.1%), alcohol use (11.0%), diabetes (9.0%), 
anemia (1.3%), nutrition status (categorized BMI, 1.1%), pre-treatment delay (0.5%), HIV status (0.4%) 
and site of TB disease (0.1%). Assuming missingness at random, multiple imputation uses a conditional 
regression-based approach to create multiple imputed data sets where missing values are estimated for each 
imputed variable from distributions conditional on specified covariates. Multinomial and standard logistic 
imputation models were fit for categorical and binary variables, respectively, using the –augment option in 
Stata to account for the presence of perfect prediction of categorical variables.47 Imputation models 
contained the 14 covariates included in the cause-specific hazards models as well as the auxiliary variables 
of the outcome of interest (loss to follow-up or death) and month of treatment registration. MICE was used 
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to generate 20 imputed data sets (Stata v13.1 -mi impute chained), and the distribution of imputed values 
for all variables was compared to the observed values to assess for any systematic differences.48 Exploratory 
data analysis of the mean and standard deviation of imputed values for each covariate suggested that ~10 
iterations prior to saving the imputed data set was adequate to ensure convergence of the algorithm 
(Supplementary Figures 2.1 and 2.2).  
 
Using the 20 imputed datasets, multivariable cause-specific hazards models were fit and the parameter 
estimates and standard errors were combined using Rubin’s formulas.49 Results from the complete-case 
analyses and the analyses following multiple imputation were compared qualitatively. The proportional 
hazards assumption for each model was assessed using log-log plots of the survival function and the 
inclusion of interactions between specific covariates and time. Goodness of final model fit was assessed 
using Cox-Snell residuals plotted against the observed cumulative hazard function. All analyses were 
conducted in Stata v13.1 (StataCorp, College Station, TX, USA). 
 
Ethical considerations: 
Ethical approval was obtained from the State Public Health Research Ethics Committee – STDC, Pune and 
Johns Hopkins School of Medicine Institutional Review Board.  
 
Results: 
Eligibility for study inclusion of public sector DR TB treatment registrations at DR TB Center – Pune 
Between January 1, 2015 and December 31, 2016, there were 1246 registrations for public sector DR TB 
treatment at the DR TB Center – Pune (Figure 2.2). XDR TB registrations (n = 99, 7.9% of all registrations), 
second MDR TB registrations during 2015 and 2016 (n = 8, 0.7% of all MDR TB registrations) and patients 
transferring in from other public sector DR TB centers after treatment initiation (n = 97, 8.5% of new MDR 
TB registrations 2015-16) were ineligible for study inclusion. Among individuals registering for a new 
course of MDR TB treatment at the DR TB Center – Pune, 101 (8.9% of new MDR TB registrations from 
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2015-16) were excluded due to unavailable pre-treatment evaluation data. The primary reason for 
unavailable data was pre-treatment evaluation conducted at a district-level public sector hospital and not at 
the DR TB Center (n = 94, 93% of unavailable pre-treatment data) with additional minor reasons being 
referrals from unspecified hospitals (n = 2), evaluation at a nearby local hospital (n = 1), and no reason 
identified (n = 4). Of the 941 individuals registered for new MDR TB treatment in 2015-16 with available 
pre-treatment evaluation data, 20 (2.1%) had unknown treatment status after PMDT registration with no 
clarifying information identified following review of follow-up sputum culture data, PMDT cards, PMDT 
registers and adjudication discussions with district-level DPSs.  
 
Characteristics of included MDR TB patients initiating public sector in 2015-2016 
For all covariates of interest, complete data was available for 740 MDR TB patients (80.3%) in the cohort 
(n = 921) with no missing values for patient age, sex and TB treatment history. Observed missingness for 
the other covariates ranged from 0.1 to 11% (102/921) (Table 2.2) with tobacco history (11%), alcohol 
history (11%) and diabetes (9%) having the highest proportion of missing values and all other covariates 
with 1.3% missingness or less.  
 
The median cohort age was 30 years (interquartile range; IQR 24-42) and 36% of included MDR TB 
patients were female. For prior TB treatment history, 28% had previously taken TB treatment in the private 
sector and 21% had been lost to follow-up from either public or private treatment. Alcohol and tobacco use, 
either current or in the past, were reported by 20% and 15% of patients, respectively. For the present 
diagnosis of MDR TB, median pre-treatment delay was 13 days (IQR 7-21, max 154) and 4.7% of patients 
had extrapulmonary TB (EP TB). Among the included EP TB cases (n = 43), 36 (84%) had available 
information on EPTB site: 20 (56%) isolated TB lymphadenitis, 6 (17%) isolated cold abscess, 4 (11%) 
pleural effusion, 4 (11%) abdominal TB and 2 (6%) TB arthritis. Of recorded comorbidities, 7% had a 
recent HIV positive test result or were on antiretroviral therapy (ART), 12% had diabetes, 77% had a body 
mass index (BMI) categorized as underweight (<18.5 kg/m2) with 49% severely underweight (<16 kg/m2); 
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and 91% had a baseline hemoglobin diagnostic of anemia with 27% mild anemia, 55% moderate and 9% 
severe. 
 
Loss to follow-up and mortality during public sector MDR TB treatment and associated factors 
The median duration of follow-up after initiating public sector MDR TB treatment was 16.6 months (IQR 
5.9-23.7) with 1127 person-years (PY) of follow-up in the cohort. Among the included individuals who had 
an official final treatment outcome declared (n = 299, i.e. enrolling in treatment before October 2015), 39% 
completed treatment or were cured, 27% died, 15% loss to follow-up, 11% transferred out, 4% switched to 
XDR TB treatment and 4% failed treatment. Among all included individuals (n = 921), 20% completed 
treatment or were cured, 21% died, 14% loss to follow-up, 8% transferred out, 7% switched to XDR TB 
treatment, 1% failed treatment and 29% were still on treatment at the time of administrative censoring. 
During follow-up for all included individuals starting treatment during 2015 and 2016, 130 were lost to 
follow-up with a median time to LTFU of 6.2 months (IQR 3.0-11.7) and a crude incidence rate of 11.5 
events per 100PY (95%CI 9.7-13.7). Regarding mortality, 194 individuals died of any cause during 
treatment with a median time to death of 5.1 months (IQR 1.7-12.0) and a crude mortality rate of 17.2 
deaths per 100PY (95%CI 15.0-19.8) (Figure 2.3).  
 
Crude loss to follow-up rates and the results of univariate and multivariable cause-specific hazards models 
for loss to follow-up are summarized in Table 2.2. The highest crude loss to follow-up rates occurred among 
the following groups in decreasing order: individuals age >55y (24.0 events per 100PY), history of alcohol 
use (23.2), history of tobacco use (20.0), any prior LTFU from TB treatment (19.2) and HIV (17.1). In the 
multivariable complete case analysis (n = 740), history of alcohol use (aHR 1.66, 95%CI 1.01-2.74) and 
HIV (aHR 2.44, 95%CI 1.21-4.91) were associated with higher loss to follow-up; female sex (aHR 0.57, 
95% CI 0.33-0.98) and any prior private TB treatment (aHR 0.56, 95%CI 0.3-0.96) were associated with 
lower loss to follow-up. Missing values for all covariates of interest were estimated in 20 imputed datasets 
using MICE. Similar adjusted relative cause-specific hazards for loss to follow-up were observed following 
28 
multiple imputation (n = 921 patients included) for history of alcohol use (aHR 1.62, 95%CI 1.01-2.67) and 
any prior private treatment (aHR 0.56, 95%CI 0.34-0.91). However, female sex and HIV were not found to 
be associated with loss to follow-up. Extrapulmonary TB, not associated with higher loss to follow-up in 
the complete case analysis, was significantly associated with higher loss to follow-up in the multivariable 
model after multiple imputation (aHR 2.14, 95%CI 1.04-4.41).  
 
Crude mortality rates and the results of univariate and multivariable cause-specific hazards models for 
mortality are summarized in Table 2.3. The highest crude mortality rates were observed among the 
following groups in decreasing order: any prior loss to follow-up from TB treatment (38.4 deaths per 
100PY), severe anemia (37.5), history of alcohol use (32.1), HIV (31.4) and severe underweight (25.5). In 
the multivariable complete case analysis (n = 740), prior loss to follow-up (aHR 2.27, 95%CI 1.56-3.32), 
moderate underweight (aHR 2.11, 95%CI 1.01-4.39) or severe underweight (aHR 3.23, 95%CI 1.78-5.87) 
vs. normal BMI or above as well as severe anemia (aHR 3.55, 95%CI 1.42-8.91) vs. no anemia were all 
associated with higher relative hazards of mortality. Treatment registration in 2016 vs. 2015 was associated 
with lower mortality (aHR 0.70, 95%CI 0.50, 0.99). Missing values for all covariates of interest were 
estimated in 20 imputed datasets using MICE separately for the mortality analysis due to the inclusion of 
death as an auxiliary variable in the imputation models. Similar adjusted relative cause-specific hazards for 
mortality were observed following multiple imputation (n = 921 patients included) with moderate anemia 
vs. no anemia also significantly associated with mortality (aHR 2.04, 95%CI 1.01-4.12).  
 
Discussion: 
In this cohort of MDR TB patients initiating public sector treatment during 2015 to 2016 in Western 
Maharashtra, overall loss to follow-up (15%) for patients with a final treatment outcome (i.e. enrolling 
before October 2015) was similar to global (16%)16 and slightly lower than national averages (20%);50 
however, mortality was found to be higher (27%) than both (16% global; 22% national). The integration of 
pre-treatment evaluation and PMDT data at the DR TB Center-level28,33 provides an opportunity to examine 
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factors not available in larger aggregate patient-level PMDT datasets.29-31 These factors include: alcohol 
and tobacco use, diabetes, anemia and a more detailed prior TB treatment history.  
 
In the present study, a history of alcohol use was consistently associated with higher loss to follow-up across 
all models (univariate, complete case - multivariable, multiple imputation - multivariable). This finding is 
similar to previously published MDR TB cohort studies.8,10,11,23,34,51 Alcohol treatment interventions 
integrated into TB care have previously been demonstrated to improve outcomes52-54 and their more routine 
incorporation into RNTCP activities provides an important opportunity to improve treatment retention and 
care in India. The association of any prior private treatment with lower loss to follow-up among those 
presenting for public sector treatment could be due to many factors, including catastrophic costs incurred 
during private treatment55-57 or a preference shift toward the public sector over the course of private 
treatment.58 Higher relative hazards of loss of follow-up among EP TB cases compared to pulmonary TB 
cases could have been confounded by site of EP TB or due to fewer symptoms or lower perceived severity 
of TB.  
 
The lower relative hazard of mortality for patients starting MDR TB treatment in 2016 compared to 2015 
suggests programmatic improvement in this crucial outcome. Trends in mortality since the inception of 
PMDT in India in 2007 to present would provide further insights into program progress.31 The trend of 
higher mortality with decreasing categories of BMI has been consistently described in prior MDR TB 
treatment outcome studies from multiple countries.8,10,31 This finding, similar to the observation of higher 
mortality with increasing anemia severity, highlight the importance of early intensive treatment 
interventions for individuals presenting with symptoms of severe disease.8 
 
The present study had several notable strengths. The integration of pre-treatment evaluation and outcome 
data27 allowed for the investigation of additional variables not frequently analyzed previously for PMDT 
data. Furthermore, through proactive discussions with program staff and DPSs regarding patient treatment 
30 
status, this study provided an opportunity to analyze more recent and potentially relevant PMDT data than 
previous studies that often wait until RNTCP has officially declared final treatment outcomes. Efforts to 
identify missing data by reviewing multiple sources as well as efforts to adjudicate discrepancies 
strengthened data quality and reduced missingness. When present, the impact of missing data on 
conclusions was evaluated by comparing complete case analyses and analyses after multiple imputation. 
Survival analysis models and Kaplan-Meier estimates of the survival function for loss to follow-up took 
into account the competing risk of death.  
 
This study also had several limitations. Information routinely recorded during pre-treatment evaluation was 
consistent for the vast majority variables but not standardized. Alcohol and tobacco use history as well as 
diabetes for example were more routinely collected after July 2015. Treatment and outcome data are 
consistently monitored and validated by RNTCP staff at multiple levels in an attempt to ensure accuracy 
and timely reporting. Treatment outcomes, although updated monthly at data review meetings, are more 
rigorously evaluated at the time of final treatment outcome declaration, 31-33 months following treatment 
initiation.38 Efforts to identify these outcomes prior to their finalization was at times challenging due to the 
decentralization of treatment and also knowledge of patient treatment status. 
 
Regarding outcome status following loss to follow-up, there is the possibility of conflating loss to follow-
up from the public sector program with an individual being off treatment entirely. In reality, individuals 
lost to follow-up at any treatment stage may be linked into other care programs (e.g. private sector) or have 
silently transferred to another public sector facility.59 Additionally, the outcomes of individuals who 
transferred out or switched to XDR TB regimens should be ascertained through conversations with other 
DR TB centers, linkage of MDR TB and XDR TB registrations of the same individuals and if necessary 
tracing efforts. The incorporation of the true outcomes (completion, cure, death, not on treatment or failure) 
of these individuals would provide more accurate epidemiologic data to guide TB programs and funding 
31 
allocation. Lastly, the present study was entirely limited to the public sector and conclusions may or may 
or not be generalizable to private sector care in India. 
 
Recent RNTCP changes have attempted to address several of the identified gaps in care. Pilot projects in 
India have demonstrated the potential of scaling-up molecular diagnostics,60 public-private partnerships,61 
and directly observed therapy by family members.62 Additional ongoing efforts include the expanded use 
of more diverse and likely effective MDR TB treatment regimens, such as: bedaquiline-containing 
regimens, shorter 9-11 month MDR TB regimens (i.e. Bangladesh regimen) and more personally tailored 
regimens based on expanded 1st and 2nd-line DST (i.e. DST-guided treatment).39 Although their use has 
been somewhat limited as of 2018, their expanded use in the near future has great potential to improve 
patient outcomes and quality of life. Nikshay, an online governmental platform for TB notification and 
monitoring in India,63,64 shows promise in facilitating reporting, data standardization,65 and research from 
the Tuberculosis Unit to the national-level. Increased funding and leadership at all levels from local 
peripheral health institutions to the central research institutions66 will, however, be essential for 
demonstration projects to be brought to scale. 
 
The investigation of the timing, extent and factors of poor treatment outcomes during public sector MDR 
TB care provides significant opportunities to guide program development and interventions to specific gaps 
in order to maximize the impact of available resources. However, undue emphasis on single components of 
the care cascade may “shift attrition downstream”67 due to weak linkages in care, implementation 
challenges and previously unidentified barriers.68 Patient-centered and integrated approaches to addressing 
access to high-quality TB diagnosis, treatment and care offer the greatest probability of reducing 
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Figure 2.1: Location of study setting in Maharashtra (Panel B), India (Panel A). Individuals enrolling in 
public sector MDR TB treatment at DR TB Center – Pune from five administrative districts in Maharashtra 
(Panel C) were eligible for inclusion. All patients enrolling in treatment in 2015 and 2016 from four districts 
(red) were eligible. Individuals from Raigad District (orange) were only referred to DR TB Center – Pune 
for treatment initiation from July 2015. Individuals from other listed districts (yellow) were referred to DR 
TB Center – Pune before 2014 but not during the study period.   
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*Diabetes: fasting blood glucose and postprandial blood glucose screen conducted if elevated random 
blood glucose or high clinical suspicion for diabetes at the time of pre-treatment evaluation 
∽RNTCP districts: Pune Rural, Pune Corporation, Pimpri-Chinchwad, Solapur Rural, Solapur 





Figure 2.2: Eligibility and inclusion of 921 MDR TB patients enrolling in public sector treatment at DR 





Figure 2.3: Cumulative incidence curves for loss to follow-up and mortality for patients enrolling in public 
sector MDR TB treatment at DR TB Center – Pune in 2015 and 2016. Cumulative incidence curves 




Table 2.2: Characteristics of MDR TB patients enrolling in public sector treatment through DR TB 
Center – Pune (n = 921), crude loss to follow-up rates and associated factors 
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Table 2.3: Characteristics of MDR TB patients enrolling in public sector treatment through DR TB 




Supplementary Figure 2.1: Representative trace plot of mean estimated imputed values of missing 
variables (above: alcohol use) over 100 iterations. Evidence of imputation algorithm converging to a 




Supplementary Figure 2.2: Representative trace plot of the standard deviation of estimated imputed values 
of missing variables (above: alcohol use) over 100 iterations. Evidence of imputation algorithm converging 
to a stationery state is seen in that traces of mean imputed values do not systematically increase or decrease 
with subsequent iterations
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Chapter III: Assessment of Baseline Quality of Life in Patients 
Initiating Multidrug-Resistant and Drug-Susceptible Tuberculosis 
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Background: Tuberculosis and its treatment have frequent and often severe consequences for patient 
quality of life. There is limited evidence however on the quality of life of individuals with multidrug-
resistant TB (MDR TB) and its comparison with drug-susceptible TB (DS TB) patients and healthy 
controls. 
 
Methods: Enrolled MDR TB, DS TB and healthy control participants from public sector diagnostic and 
treatment facilities in Pune, India were interviewed to compare quality of life using the WHOQOL-BREF 
questionnaire and other covariates of interest. Factors associated with quality of life were assessed using 
univariate and multivariable linear regression models.  
 
Results: Overall, 236 participants were enrolled (80 MDR TB, 79 DS TB and 77 healthy controls). In 
multivariable linear regression models, quality of life was observed to be significantly lower for both TB 
groups compared to healthy controls in the physical (DS TB-18.4, 95%CI -24.7, -12.0; MDR TB -23.1, 
95%CI -29.3, -16.9) and psychological (DS TB -15.7, 95%CI -22.7, -8.7; MDR TB -20.0, 95%CI -26.9, -
13.1) domains and for MDR TB patients in the social domain (DS TB -4.9, 95%CI -10.6, 0.8; MDR TB       
-9.7, 95%CI -16.1, -3.3). MDR TB patient quality of life was consistently lower, although not statistically 
significant, than DS TB patient quality of life across all four domains except environmental. Broadly, lower 
quality of life scores were significantly associated with increased comorbidity severity and lower household 
assets. Lower social quality of life was also associated with lower education (-0.6 per year of less education, 
95%CI -1.2, -0.1) as well as a marital status of separated, divorced or widowed vs. currently married (-16.0, 
95%CI -26.2, -5.7). Lower environmental quality of life was associated with alcohol dependence (-9.5, 




Conclusions: Quality of life is impaired in TB and MDR TB patients compared to healthy controls. 
Identified factors associated with quality of life highlight the importance of behavioral and social factors 





Traditionally, the primary goal of tuberculosis (TB) treatment has been to achieve the important clinical 
and public health outcome of microbiological cure. Less emphasis, however, has been placed on morbidity 
and patient-reported outcomes.1 It is well known that TB and its treatment have frequent and often severe 
physical, psychological and social ramifications for patients and their families with some sequelae 
extending long after treatment completion. The impact of drug susceptible TB (DS TB) on respiratory 
health impairment,2 depression,3 social stigma,4 and high financial costs5 among others have all been 
identified previously. Some of the substantial challenges of multidrug-resistant TB (MDR TB) and its more 
toxic and lengthy treatment regimens have also been documented with negative impacts on multiple 
domains of patients’ lives.6-8  
 
Health-related quality of life (QOL) is a multi-dimensional construct that defines health as physical, mental 
and social well-being rather than strictly the absence of disease.9 Many generic (i.e. not focused on any 
specific disease or condition) and disease-specific instruments have been developed to measure an 
individual’s perceived quality of life across a wide range of health-related domains. These patient-reported 
outcome measures are not a substitute for important clinical or microbiological outcomes, such as sputum 
conversion, but are rather complementary in that they provide a more nuanced understanding of the impact 
of disease and its treatment on patients. The utilization of these measures clinically or programmatically 
provide important opportunities to screen for and prioritize problems faced by patients, facilitate 
communication with health providers or program staff and monitor responses to treatments or 
interventions.10,11 Additionally, patient-reported outcomes have also been found to be associated with 
poorer traditional outcomes, such as loss to follow-up and mortality.12,13  
 
The World Health Organization QOL-BREF (WHOQOL-BREF) questionnaire and variations of the 
Medical Outcomes Study Short Form (SF) questionnaire (e.g. SF-36, SF-12) are two of the most frequently 
used generic instruments to examine quality of life, including among individuals with TB.14,15 These 
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instruments have both been translated in multiple languages and validated in several settings and among 
diverse populations. The WHOQOL-BREF, compared to other generic quality of life instruments such as 
SF-36 and EuroQOL-5D, captures more subjective perceptions of health and well-being as opposed to more 
objective information regarding health-related functioning and disability.16-18 Although TB-specific quality 
of life scales have been developed, such as FACIT-TB19 and DR-12,20 they have not been adequately 
examined and are to date not widely used. Additionally, as quality of life measures become more disease-
specific, they are less useful in comparing health outcomes across different populations and groups, 
including healthy controls.21 Other generic and disease-specific questionnaires focusing on specific 
dimensions of quality of life have also been examined among individuals with TB. These scales and the 
dimensions covered include but are not limited to: Patient Health Questionnaire-9 (PHQ-9),22 Beck 
Depression Inventory (BDI), Center for Epidemiologic Studies Depression Scale (CES-D) for depressive 
symptoms; Explanatory Model Interview Catalogue [EMIC]23 and internalized social stigma scale24 for 
stigma; and St. George Respiratory Questionnaire (SGRQ) for lung health.2,25 
 
Prior systematic reviews and meta-analyses of quantitative quality of life studies for individuals with TB 
have identified that TB has a negative impact on quality of life compared to individuals with latent TB 
infection or healthy controls. In a limited number of longitudinal studies, significant improvements in 
quality of life have been observed over the course of treatment; however, residual impairment was common 
after treatment even among cured individuals.2,26,27 These prior QOL studies have however been found to 
have several notable limitations: lack of comparison groups, limited descriptions of inclusion criteria and 
sampling mechanisms for healthy controls, little information about the recruitment process, limited data on 
key social and behavioral determinants of QOL and minimal inclusion of key groups likely to have more 
greatly impaired QOL such as individuals with MDR TB.14,15,28  
 
The present cross-sectional study aimed to address several of these limitations by comparing baseline 
quality of life for newly diagnosed MDR TB and DS TB patients initiating public sector treatment to TB-
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negative healthy controls in Pune, India. Given our objective of trying to understand the broad impact that 
TB has on QOL from the patient’s perspective, the generic WHOQOL-BREF instrument was used for QOL 
assessments. Among the three included groups, it was hypothesized that quality of life among MDR TB 




The study was conducted from August 11, 2017 to May 14, 2018 in Pune (PMC) and Pimpri-Chinchwad 
Municipal Corporations (PCMC) in Maharashtra, India. In 2017, these two municipal corporations had a 
population of approximately 6.8 million people with 5400 individuals initiating public sector DS TB 
treatment and 180 initiating public sector MDR TB treatment.29  
 
Study participant eligibility criteria and recruitment: 
Three main groups were included for comparison in the present quality of life study: MDR TB patients and 
DS TB patients initiating public sector treatment and healthy controls testing negative for TB by sputum 
smear at public sector microscopy centers. Inclusion and exclusion criteria for all study groups are 
summarized in Table 3.1.  
 
MDR TB patients were eligible if the following inclusion criteria were met: (1) ≥18 years of age; (2) 
diagnosed with MDR or rifampicin resistant (RR) pulmonary or extrapulmonary TB by molecular or 
culture-based DST; (3) initiation of public sector MDR TB treatment (i.e. category IV) in PMC or PCMC 
between July 13, 2017 and April 21, 2018; (4) on treatment for <2 months before study interview; (5) ability 
to communicate in Marathi, Hindi or English; and (6) provision of written informed consent. In the study 
area, standardized MDR TB treatments were used in the public sector program and consisted of a 6 to 9-
month intensive phase of 6 drugs (kanamycin, levofloxacin, ethionamide, pyrazinamide, ethambutol and 
cycloserine) followed by an 18-month continuation phase of 4 drugs (levofloxacin, ethionamide, 
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ethambutol and cycloserine) with weight-based dosing (i.e. 6-9 Km Lfx Eto Cs ZEH + 18 Lfx Eto Cs E H). 
Consecutive individuals starting MDR TB treatment within the study period and area were approached for 
possible enrollment. 
 
No centralized registries, either computer or paper-based, were available in the study area to facilitate the 
random sampling of potential DS TB or healthy control participants in PMC and PCMC. As a result, one 
DS TB patient and one healthy control were randomly selected for each enrolled MDR TB patient from the 
sub-district-level (i.e. Tuberculosis Unit, TU) DS TB treatment and designated microscopy center (DMC) 
registers, respectively. For the 2-week period after treatment initiation for each MDR TB patient, a list was 
made of potentially eligible DS TB patients starting treatment and individuals providing a sputum sample 
for TB screening. The screening order of enumerated individuals for each group was assigned using a 
random number generator. DS TB patient inclusion criteria were the same as for MDR TB patients with the 
following differences: (1) diagnosed with pulmonary or extrapulmonary TB without any documented 
evidence of rifampicin resistance, and (2) initiation of public sector DS TB treatment (i.e. either category I 
or II) in Pune and Pimpri-Chinchwad MCs within 2 weeks of the corresponding MDR TB patient. Category 
I treatment is given through the public sector program to newly diagnosed TB patients without a prior 
history of treatment. Category II treatment is administered to individuals with a prior treatment history of 
TB for any reason, including: treatment failure, sputum culture follow-up positive, treatment after loss to 
follow-up or prior private treatment. The duration of category I treatment is 6 months, consisting of a 2-
month intensive phase of 4 drugs (isoniazid, rifampicin, pyrazinamide and ethambutol) followed by a 4-
month continuation phase of 3 drugs (isoniazid, rifampicin and ethambutol) (i.e. 2HRZE + 4HRE). 
Category II treatment is similar with a 3-month intensive phase using the same drugs as category I but with 
the addition of the injectable drug streptomycin for the first two months; the category II continuation phase 




Healthy controls were identified by randomly screening adults (≥18 years of age) recorded in corresponding 
TU-level DMC registers to have two negative sputum smears for TB and an available telephone number. 
Due to the reliance on sputum smear microscopy for TB diagnosis in the study area, potentially eligible 
individuals were also screened prior to enrollment for self-reported TB treatment as well as TB symptoms 
in an attempt to minimize the possible inclusion of individuals with diagnosed or undiagnosed TB into the 
healthy control group. The symptom screen consisted of 5 self-reported TB-related symptoms: cough ≥2 
weeks, fever, hemoptysis during the previous year, night sweats and unintentional weight loss. In a large 
study among HIV-negative individuals in Zimbabwe, a similar symptom screen (any cough instead of 
prolonged cough) had a sensitivity of 71.0% and specificity of 90.3% for active TB disease.30 Prior to 
enrollment, potential healthy controls were also considered ineligible if they reported any of the following 
14 additional medical conditions included in the self-administered comorbidity questionnaire (SCQ)31 and 
often excluded in other QOL studies:14,15 heart disease, high blood pressure, lung disease, diabetes, ulcer or 
stomach disease, kidney disease, liver disease, anemia or other blood disease, cancer, depression or other 
psychiatric condition, osteoarthritis, chronic back pain, HIV and pregnancy.  
 
Data collection and variables: 
A semi-structured questionnaire was developed to examine the quality of life of and challenges faced by 
individuals initiating public sector MDR and DS TB treatment. Available Hindi and Marathi translations 
of the included quality of life (WHOQOL-BREF) scale were obtained with permission from the World 
Health Organization (WHO, http://www.who.int/substance_abuse/research_tools/whoqolbref/en/). The 
remaining sections of the questionnaire were translated into Marathi and Hindi by local translators with 
substantial experience in clinical research studies. Translations were revised based on reviews by study 
interviewers and a local anthropologist and then pilot tested among 5 eligible MDR TB and DS TB patients 





The final questionnaire consisted of four total sections: (1) demographic, (2) quality of life, (3) social and 
economic, (4) clinical and substance use. The primary outcomes in this analysis were the four separate 
domains of WHOQOL-BREF. This questionnaire is composed of a subset of questions from the larger 
WHOQOL-100 instrument, and it includes a total of 26 items, two separate general QOL questions and 24 
items encompassing 4 health-related domains: physical, psychological, social, and environmental.  
 
Information on gender identity, marital status, religion, education, employment status, as well as 
socioeconomic status of the participant and the participant’s household were also collected. Questions on 
household assets were utilized to create an equally weighted index variable of participant living standards 
that included ownership of the following items: radio, refrigerator, television, phone or mobile, bicycle, 
motorcycle and car. This living standard index variable, with possible values ranging from 0 to 7, was then 
categorized at the 25th, 50th and 75th percentiles of all participants. 
 
Information on prior TB diagnoses and treatment as well as HIV were recorded in the clinical history. 
Comorbidity information was collected using the Self-administered Comorbidity Questionnaire (SCQ) 
adapted for interviewer administration.31 This questionnaire includes questions about the presence of 12 
diseases and disease categories: heart disease, high blood pressure, lung disease, diabetes, ulcer / stomach 
disease, kidney disease, liver disease, anemia, cancer, depression, osteoarthritis, back pain, rheumatoid 
arthritis and also includes space to enter three additional conditions if applicable. For each reported 
comorbidity, two follow-up binary questions (0 = no, 1 = yes) are included regarding the limitation of 
activities due to the comorbidity and current treatment status, resulting in an overall score of 0-3 points for 
each condition. The overall score from the SCQ, summing responses for all 15 possible conditions, ranges 
from 0-45.  
 
Information on study participant alcohol use was recorded using the Alcohol Use Disorders Identification 
Test, Consumption (AUDIT-C). This scale, developed by WHO, includes three questions on the frequency 
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of alcohol consumption and amount of alcohol consumed in terms of standard drinks (10g ethanol 
equivalents for India) in order to identify hazardous drinking or potential alcohol abuse or dependence.32 
Due to documented underestimation of alcohol consumption, a simplified photograph approach was used 
to capture information about volume consumed.33 During pilot testing, interviewers noted difficulty 
translating alcoholic drinks consumed into standard drinks due to the variety of beverages. During the study 
for the AUDIT-C consumption question, participants were asked only about what alcoholic beverages they 
normally consumed and the volume. Conversions to standard drinks were made at the time of data entry 
using a review of alcoholic drinks and ethanol content in the three Indian states of Goa, Rajasthan and 
Delhi.34 Each of the three AUDIT-C questions was coded from 0 to 4 with a possible scale range of 0 to 12. 
This scale has previously been demonstrated in India to have the highest combined sensitivity and 
specificity for alcohol use disorders when using a cutoff of ≥5.35 Additionally, tobacco smoking use was 
also measured as a categorical variable: current smoker, former smoker, and never smoked.  
 
Interviewers were hired from the study area and trained for 1 month on the questionnaire, underlying scale 
constructs and interviewing skills. Preliminary work also included visits to each local participating TU to 
establish strong working relationships and to gain perspective on public sector program activities. Study 
staff had no involvement in clinical care and interviews were conducted at the public sector TB program 
hospital or dispensary considered most convenient for the participant. All interviews with TB patients were 
scheduled greater than 10 days after treatment initiation to minimize the risk of transmission to study staff. 
Prior to each interview, written informed consent was obtained, and after the interview participants were 
reimbursed a fixed amount for local travel to the clinic as well as lost wages based on local Institutional 
Review Board recommendations.  
 
Data were entered into a Microsoft Access database using EpiInfo v7.0. All completed questionnaires were 
reviewed after data entry and any issues identified were cross-checked using the completed forms and 




WHOQOL-BREF domain scores were calculated as the average 5-point Likert response of questions within 
each respective domain (Table 3.2). Scores were then transformed to a 0-100 scale to allow for the 
comparison of domains with different numbers of questions.18 The internal consistency of each domain was 
evaluated using Cronbach’s alpha where >0.70 indicated was considered adequate. Internal convergent and 
discriminant construct validity were examined by comparing the polychoric correlation coefficients for 
ordinal variables of individual indicators to the four WHOQOL-BREF global quality of life questions.9,36  
 
In the recruitment process, there were no attempts at frequency matching DS TB and healthy control 
participants on key covariates of interest, such as sex, age and site of TB disease (pulmonary vs. 
extrapulmonary). These variables and TB treatment category were available for all DS TB patients screened 
from public sector treatment registers. Sex and age information were available for all healthy controls 
screened from public sector microscopy center registers. To examine the potential for selection bias of 
participants, univariate and multivariable logistic regression models were fit using enrollment in the study 
as the outcome variable in order to identify factors associated with higher odds of participation. 
 
In descriptive analyses, WHOQOL-BREF domain scores were summarized for MDR TB, DS TB and 
healthy control individuals using box plots. Covariates of interest were summarized by participant group 
and univariate comparisons performed using Fisher’s exact test for categorical variables and Kruskal-Wallis 
rank test for continuous variables. Simple and multivariable linear regression models were used to compare 
WHOQOL-BREF domain scores across levels of each covariate of interest. Covariate selection was a priori 
and informed by the study’s conceptual model (Chapter 1, Figure 1.1) and literature review. Due to 
potential selection bias in DS TB patient recruitment, a sensitivity analysis was performed by repeating the 
final multivariable models after restricting all participants with TB to only pulmonary cases and DS TB 
participants to only those undergoing category I treatment. Regression diagnostics for all multivariable 
linear models included: augmented component-plus-residual plots (linearity assumption), quantile-normal 
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and quantile-quantile plots of residuals (normality assumption), and plots of residuals vs. fitted values for 
each covariate of interest (homoscedasticity). Robust standard errors were used in all final multivariable 
models for each WHOQOL-BREF domain to account for heteroscedasticity. Multicollinearity was 
evaluated by checking for large variance inflation factors (>10) for each included covariate. All statistical 
analyses were conducted in Stata v13.1 
 
Human research ethics approvals: 
Ethics committee approval was obtained from the State Public Health Research Ethics Committee at Aundh 
Chest Hospital and Johns Hopkins University School of Medicine Institutional Review Board. 
 
Results: 
Participant screening and recruitment: 
Screening and recruitment for all three study groups are summarized in Figure 3.1. Between July 2017 and 
April 2018, there were 177 registrations for public sector DR TB treatment in PMC and PCMC, of which 
38% were not eligible for the study: 32 (18%) XDR-TB treatment initiations, 18 (10%) treatment initiations 
in a non-participating TU, 8 (5%) children or adolescents <18 years of age and 10 (6%) individuals either 
transferred out of the study area before screening or initiated treatment elsewhere and transferred in. Among 
the 109 (62%) individuals starting MDR TB treatment eligible for the study, nine (5%) declined to be 
interviewed with the most common reason being a lack of time. Sixteen eligible individuals (9%) were 
unable to be screened or interviewed due to the following: death (n = 6) or loss to follow-up (n = 2) before 
screening, illness or hospitalization (n = 4), lack of a suitable interview location (n = 3) and inability to give 
consent due to disability (n = 1). Overall, 80 individuals with MDR TB were recruited and interviewed 
within 2 months of starting treatment (median 22.5 days, IQR 18-28). In a multivariable logistic regression 
model including sex, age, TB site and TU of treatment registration, willingness to be interviewed was not 
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associated with sex or site of TB (pulmonary vs. extrapulmonary); however, lower recruitment was strongly 
associated with increasing age (aOR 0.46 for each 10 year increase in age, 95%CI 0.29-0.72). 
 
For the DS TB patients, a total of 149 adult pulmonary and extrapulmonary TB patients were screened that 
had registered for public sector treatment within 2 weeks of each enrolled MDR TB patient. At the time of 
screening, five individuals did not meet the inclusion criteria for the following reasons: did not think they 
had TB (n = 2, 1% of screened), were participating in a TB clinical trial and not taking standard public 
sector treatment (n = 2, 1%) or did not speak Marathi, Hindi or English (n = 1, 1%). Among the 144 eligible 
individuals screened (97%) for willingness to participate in the study, 28 (19%) declined to be interviewed 
with the majority (n = 18) stating they did not have enough time. Additionally, 37 individuals were unable 
to be screened or interviewed due to death before screening (n = 1), illness or hospitalization (n = 14), travel 
outside of PMC or PCMC for an extended period of time (n = 9), inability to contact due to a change in 
phone number (n = 4) or not receiving phone calls from study staff (n = 9). Overall, 79 individuals with DS 
TB (53% overall, 55% of eligible) were recruited and interviewed within 2 months of starting treatment 
(median 21 days, IQR 16-31). Each completed interview required a median of 3 individuals screened (IQR 
1-3). In a multivariable logistic model for enrollment that included gender, age, TB treatment category (I 
vs. II) site of TB (pulmonary vs. extrapulmonary), TU and month of treatment initiation, higher enrollment 
was strongly associated with treatment category II (aOR 4.3, 95%CI 1.3-14.4) and extrapulmonary TB 
(aOR 4.2, 95%CI 1.5-11.5).  
 
For the healthy control group, a total of 333 individuals were screened who had tested negative for TB by 
two sputum smears at public sector microscopy centers in the same TU as enrolled MDR TB participants. 
Among those screened for eligibility, 71 (21%) did not meet inclusion criteria: 28 (8%) had at least one 
TB-related symptom, 23 (7%) reported that they had been diagnosed with TB or were on TB treatment and 
20 (6%) reported that they had at least one comorbidity. An inability to communicate with eligible healthy 
controls was one of the main challenges in recruitment. Of individuals randomly selected from microscopy 
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center registers, 74 (22% of enumerated) did not answer multiple phone call attempts from study staff and 
40 individuals (12%) had an incorrect phone number recorded in the register. Four individuals (1%) had 
also died prior to screening. Of those that were successfully contacted, 53 declined to be interviewed due 
to primarily a lack of time (n = 34) but also due to travel outside of the study area (n = 12) or no reason 
provided (n = 19). Overall, 77 healthy controls were interviewed within two months of sputum collection 
for TB diagnosis. Each completed interview required a median of 6 individuals screened (IQR 3-8). In a 
similar model fit for DS TB enrollment, healthy control participation was not associated with sex or age. 
At the time of data review, two interviews were found to have occurred later than two months from sputum 
collection (64 and 88 days) and were dropped from the analysis. 
  
Characteristics of included MDR TB, DS TB and healthy control participants 
In total 80 MDR TB patients, 79 DS TB patients and 77 healthy controls were interviewed, and all 
participants had complete data (Table 3.3). Overall, the median age of participants was 30 years (IQR 24-
41), 54% were female, the majority had a secondary education or lower (median 9 years, IQR 5-12 years) 
and 57% were primarily working either full or part-time over the last year. Education was found to be 
significantly different across the three groups (p = 0.020, Kruskal-Wallis rank test), lower among DS TB 
patients (median 8 years, IQR 3-11) compared to MDR TB patients (median 10 years, IQR 6-12) and 
healthy controls (median 9 years, IQR 7-13). Occupational status was also found to be different across the 
three groups (p <0.001, Fisher’s exact test) with MDR TB patients more likely to have reported an inability 
to work, due to illness or disability (16%) compared to DS TB patients (5%) and healthy controls (0%). In 
clinical history, MDR and DS TB patients had higher comorbidity scores than healthy controls as expected 
given study inclusion criteria. Participants with MDR TB also had significantly longer prior TB treatment 
histories (median 4.5 months, IQR 0-9) compared to DS TB patients (median 0 months, IQR 0-1) and 
healthy controls (median 0 months, IQR 0-0). Individual smoking tobacco use and alcohol dependence as 
well as household size and assets were not significantly different across groups. Due to lengthier screening 
efforts required for recruitment, days from baseline (i.e. treatment initiation or sputum collection) to study 
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interview were significantly longer for healthy controls (median 30 days, IQR 21-38) than MDR TB 
patients (median 22.5 days, IQR 18-28) and DS TB patients (median 21 days, IQR 16-31).  
 
Psychometric properties of WHOQOL-BREF in study population 
Each WHOQOL-BREF domain was found to have adequate internal consistency as assessed by a 
Cronbach’s alpha score of >0.70: physical domain (0.886), psychological (0.875), social (0.789), 
environment (0.788). Internal construct validity was evaluated by comparing the polychoric correlations 
between individual indicator responses and domain scores. All indicators in the physical, psychological and 
social domains were most highly correlated with their respective domain scores. The environmental domain 
indicator on safety was more highly correlated with the psychological domain score, a finding that has been 
documented previously at some research sites.9  
 
Quality of life and associated factors among MDR TB, DS TB and healthy control participants 
Overall, WHOQOL-BREF domain scores were significantly higher for healthy controls than both MDR 
TB and DS TB participants (Figure 3.2). Univariate and multivariable linear regression models for each 
transformed WHOQOL-BREF domain score (scale 0-100) were fit to compare quality of life across MDR 
TB, DS TB and healthy control participants before and after adjusting for other covariates. In unadjusted 
analyses, quality of life for healthy controls was significantly higher than both MDR TB and DS TB 
participant groups for all domain scores (results not shown). Physical, psychological and social quality of 
life were lower for MDR TB patients than DS TB patients; however, this association was only significantly 
different for the physical domain score ( 5.9, 95%CI 0.03, 11.7).  
 
In multivariable models, quality of life for both TB groups was significantly lower than healthy controls 
for the physical domain (DS TB vs. control  -18.4, 95%CI -24.7, -12.0; MDR TB vs control  -23.1, 
95%CI -29.3, -16.9) and the psychological domain (DS TB vs. control  -15.7, 95%CI -22.7, -8.7; MDR 
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TB vs. control  -20.0, 95%CI -26.9, -13.1). Compared to controls, social quality of life was significantly 
lower for MDR TB ( -9.7, 95%CI -16.1, -3.3) but not DS TB patients ( -4.9, 95%CI -10.6, 0.8). 
Environmental quality of life was similar across all three groups in multivariable models. As the primary 
study hypothesis was that MDR TB quality of life would be lower than DS TB quality of life followed by 
healthy controls, coefficient estimates in Table 3.4 are displayed with MDR TB participants as the reference 
group. Quality of life domain scores in adjusted models were lower for MDR TB patients compared to DS 
TB patients but not significantly different for the physical ( -4.7, 95%CI -11.6, 2.1), psychological ( -
4.3, 95%CI -11.2, 2.6) and social domains ( -4.8, 95%CI -10.8, 1.3).  
 
Regarding associations between quality of life and other included covariates, lower quality of life was 
consistently associated with increasing comorbidity scores (SCQ) for all domains: physical ( -2.1 per point 
on the SCQ scale, 95% CI -3.4, 0.8), psychological ( -1.7, 95%CI -2.6, -0.6), social ( -2.4, 95%CI -3.7, 
-1.2) and environmental ( -1.0, 95%CI -1.8, -0.2). Lower physical quality of life was not significantly 
associated with any other covariate examined but was marginally associated with female gender (vs. male 
 -5.9, 95%CI -12.3, 0.4). Lower psychological quality of life was marginally associated with alcohol 
dependence (AUDIT-C ≥5,  -6.9, 95%CI -14.6, 0.8 and an inability to work (vs. full or part-time work, 
 -10.5, 95%CI -22.7, 1.7). Lower social quality of life was associated with a marital status of separated, 
divorced or widowed ( -16.0, 95%CI -26.2, -5.7) compared to currently married. Higher education was 
associated with both higher social quality of life ( 0.6 per year of education, 95%CI 0.1, 1.2) and 
environmental quality of life ( 0.6, 95%CI 0.1, 1.1). Lower environmental quality of life was significantly 
associated with alcohol dependence ( -9.5, 95%CI -15.6, -3.5).  
 
As a proxy of socioeconomic status, each participant was asked about seven household assets. Compared 
to participants with the lowest quartile of household assets (0-2 assets), those with the highest quartile (5-
7) were observed to have higher psychological ( 9.9, 95%CI 2.9, 16.8), social ( 10.2, 95%CI 4.0, 16.5) 
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and environmental quality of life ( 9.7, 95%CI 4.2, 15.3). In a sensitivity analysis, the direction and 
magnitude of all multivariable linear regression parameter estimates were robust to the exclusion of all 
extrapulmonary TB patients and DS TB patients on category II treatment. 
 
Discussion: 
In this cross-sectional study of baseline quality of life among TB patients starting public sector treatment 
in Pune, India, quality of life was found to be broadly lower for participants with TB compared to healthy 
controls. Quality of life for MDR TB patients was lower than DS TB patients in the physical, psychological 
and social domains of the WHOQOL-BREF questionnaire but no differences were statistically significant. 
Prior systematic reviews and meta-analyses of quantitative quality of life studies among individuals with 
TB, have identified a significant negative impact of TB on quality of life compared to control groups 
measured by diverse generic and disease-specific questionnaires.14,15 Multiple studies on DS TB patient 
quality of life in India have had similar findings.26,37-42   
 
Few prior studies on MDR TB patient quality of life were identified. The majority of published research 
has focused on post-MDR TB treatment sequelae, identifying residual impairments in respiratory health 
and continued symptoms.2,27,43,44 Identified cross-sectional studies that have included MDR TB patients 
have observed lower quality of life across multiple domains compared to DS TB patients or healthy 
controls. These studies however have been limited by the lack of a healthy control group45,46, unclear 
inclusion criteria,47 interviews over wide time periods during treatment45,47 and observed associations 
unadjusted for potential confounders.47 A recent longitudinal study of MDR TB patients on programmatic 
treatment in Pakistan, using the SF-36 quality of life questionnaire, identified impaired baseline physical 
and mental quality of life with improvements over the course of treatment.48 This study thought to be the 
first longitudinal quality of life study including MDR TB patients did not include any control groups, either 




Prior quality of life studies among individuals with TB have been limited by a lack of social and behavioral 
determinant information, including alcohol use, smoking and socioeconomic status.14 In the present study, 
alcohol dependence (AUDIT-C score ≥5) was associated with lower environmental quality of life. This 
finding further highlights the importance of potential alcohol treatment interventions in TB care where 
alcohol use reported at baseline or over the course of treatment has also been associated with poor treatment 
outcomes, such as loss to follow-up.49-51 Higher numbers of household assets as a proxy for socioeconomic 
status, were found to be significantly associated with higher quality of life across all domains of WHOQOL-
BREF except for the physical domain. A longitudinal study among DS TB patients in northern India26 had 
a similar finding using a scale developed by Tiwari et al.52 The most consistently significant factor 
associated with lower quality of life in the present study was increasing comorbidity severity as measured 
by the SCQ. Prior research among TB patients has demonstrated the added negative impact of single 
comorbid conditions, such as diabetes on quality of life53 and HIV on quality of life as well as treatment 
outcomes.6,50 Multimorbidity, often defined as the presence of two or more chronic conditions,54 can 
substantially complicate TB care at levels ranging from pharmacokinetics and drug interactions55,56 to 
healthcare seeking, psychological distress and socioeconomic disadvantage.6,57 Vertical public sector TB 
program structures can complicate linkages with other services and programs. Continued efforts in India’s 
TB program to link TB care with HIV diagnosis and treatment as well as other social services will likely 
improve treatment outcomes and quality of life.29 
  
The present study aimed to address several previously identified limitations of prior TB quality of life 
studies. Both DS TB and healthy control comparison groups were included and methods of enumeration 
and sampling discussed. Data on the screening and recruitment process was documented and identified 
potential selection bias regarding significantly lower rates of participation for pulmonary DS TB patients 
and DS TB patients on Category I treatment. In a secondary analysis restricting the final multivariable 
models of WHOQOL-BREF domains to only pulmonary TB patients and DS TB patients on Category I 
treatment provided some evidence that the results were robust to this possible bias. Social and behavioral 
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determinants of quality of life, not frequently included in prior studies, were included in this study and 
found to be highly significant predictors of quality of life domains.  
 
This study also had important limitations. Participants were recruited exclusively from the public sector TB 
program and did not include individuals from India’s complex and vast private sector.58 The overall sample 
size for each study group was small. Despite potential issues in lack of statistical power to detect differences 
between MDR TB and DS TB patients, large and highly significant differences were observed for physical, 
psychological and social quality of life domains comparing TB patients and healthy controls. Quality of 
life scales are also not without criticism, including: the individual nature of quality of life, the differential 
importance of domains depending on person and place as well as the potential for lack of inclusion of what 
participants find most important.21,59,60 Observed associations in the present study may have also been 
confounded by important covariates not included in the present analysis and relevant only to individuals on 
TB, such as symptom severity, TB-related stigma, clinical experience and TB knowledge. Lastly, the study 
was cross-sectional in nature and longitudinal trends in quality of life, which have been identified 
previously,26 were not examined. For enrolled participants in PMC, follow-up interviews at 2 and 6 months 
after treatment initiation or sputum collection are ongoing, and will provide important information on these 
quality of life trends. 
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Table 3.1: Inclusion and exclusion criteria for MDR TB, DS TB and healthy control participants 
MDR TB patients DS TB patients Healthy controls 
Inclusion criteria: 
1) Adults (≥18 years of age) at 
enrollment 
 
2) Diagnosed pulmonary or 
extrapulmonary TB with 
detected rifampicin resistance by 
molecular or culture-based drug 
sensitivity testing 
 
3) Initiating public sector MDR TB 
treatment (category IV) within 
Pune or Pimpri-Chinchwad 
Municipal Corporations  
 
4) Able to be interviewed within 2 
months of treatment initiation 
 
5) Understand spoken Marathi, 
Hindi or English  
 
6) Provide informed consent  
 
Inclusion criteria: 
1) Adults (≥18 years of age) at 
enrollment 
 






3) Initiating public sector DS TB 
treatment (category I or II) 
within the same Tuberculosis 
Unit as the corresponding 
enrolled MDR TB participant 
 
4) Able to be interviewed within 2 
months of treatment initiation 
 
5) Understand spoken Marathi, 
Hindi or English 
 
6) Provide informed consent  
Inclusion criteria: 
1) Adults (≥18 years of age) at 
enrollment 
 
2) Testing negative for pulmonary 
TB on two sputum smears per 
public sector TB program 
protocol 
 
3) Presenting for TB evaluation in 
same Tuberculosis Unit as the 
corresponding enrolled MDR 
TB participant 
 
4) No self-reported TB-related 
symptoms: cough ≥2 weeks, 
fever, hemoptysis during the 
previous year, night sweats and 
unintentional weight loss 
 
5) No history of major 
comorbidities, including: heart 
disease, high blood pressure, 
lung disease, diabetes, HIV, 
tuberculosis, etc. 
 
6) Contact number recorded in the 
microscopy center register 
 
7) Able to be interviewed within 2 
months of sputum testing 
 
8) Understand spoken English, 
Hindi, or Marathi 
 
9) Provide informed consent 
 
Exclusion criteria (all participants): 
1) Children (<18 years of age) at the time of treatment initiation 
2) Presence of any condition that in the opinion of study investigators would make participation in the study unsafe, 
complicate interpretation of study results, or interfere with achieving the aims of the study 
 
‡MDR-TB suspect criteria leading to molecular or culture-based drug sensitivity testing:49 
1) Sputum smear (+) or (-) TB patient who has received >1 month of previous TB treatment;  
2) Sputum smear (+) patient without prior treatment >1 month, remaining smear (+) after ≥2 months of treatment; 
3) HIV-TB co-infection;  
4) Close contact of known MDR-TB case 





Table 3.2: Correlation matrix of WHOQOL-BREF indicator variables and domain scores with domain-











Figure 3.2: WHOQOL-BREF domain scores by study group: multidrug-resistant tuberculosis patients 
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Background: Household contacts (HHCs) of multidrug-resistant tuberculosis (MDR TB) cases are at high 
risk of infection and subsequent disease due to prolonged exposure in shared environments. There is limited 
evidence on the willingness of MDR TB HHCs to take preventive therapy that might decrease their risk of 
TB. 
 
Methods: Enrolled HHCs of MDR and rifampicin resistant (RR)-TB index cases from 16 clinical research 
sites in 8 countries were interviewed to assess willingness to take a newly developed MDR TB preventive 
therapy. To identify factors associated with willingness, marginal logistic models were fit using generalized 
estimating equations (GEE) to account for household-level clustering.  
 
Results: Overall, HHC willingness to take preventive therapy was high (79%). Site-level variation in 
willingness was observed (site-level median 90%, IQR 84-95%;) and was particularly low at one site in 
India (7%). Increased willingness was significantly associated with current employment or schooling 
[adjusted Odds Ratio (aOR) 1.82, 95% confidence interval (CI) 1.06-3.12], appropriate TB-related 
knowledge (aOR 2.23, 95%CI 1.24-4.03), confidence in taking preventive therapy (aOR 7.34, 95%CI 3.39-
15.91), and being comfortable telling others about taking preventive therapy (aOR 2.29, 95%CI 1.28-4.09). 
Decreased willingness was associated with any drug use in the past year (aOR 0.28, 95%CI 0.10-0.78).  
 
Conclusions: The high percentage of HHCs of MDR/RR-TB index cases willing to take a newly developed 
MDR TB preventive therapy provides important evidence for the potential uptake of effective preventive 
therapy when implemented. Identified HHC-level variables associated with willingness may inform 







Tuberculosis (TB) is the leading infectious disease cause of mortality worldwide with an estimated 10.4 
million new cases and 1.7 million deaths in 2016 alone.1 Multidrug-resistant (i.e. resistant to at least 
isoniazid and rifampicin; MDR) and rifampicin resistant-TB (RR-TB) are estimated to have caused 600,000 
of these new cases and a disproportionately high number of deaths.1 Household contacts (HHCs) of 
individuals with active TB are at high risk of infection due to prolonged exposure in shared environments.2,3 
Furthermore, the development of active MDR TB disease among HHCs2-4 has severe implications for 
already TB-affected households due to poor treatment outcomes despite lengthy, costly and toxic 
regimens.5,6 Prevention of MDR TB disease, therefore, remains a critical public health priority. 
 
Preventing new TB cases through the treatment of latent TB infection (LTBI) among persons exposed to 
an infectious TB case is a pillar of TB control programs. Isoniazid and rifamycin-containing regimens have 
been demonstrated to reduce the risk of TB disease among HHCs exposed to drug susceptible TB (DS 
TB).7-9 However, observational studies on MDR TB preventive therapy, primarily describing the use of 
fluoroquinolone-based regimens, have been inconclusive resulting in a conditional recommendation for 
treatment of only high risk HHCs.4,9,10 Ongoing clinical trials are evaluating new potential regimens to treat 
MDR TB infection,11 but little evidence exists on the willingness of household contacts to take preventive 
therapy were it available.  
 
Studies of knowledge, attitudes and practices have the potential to provide insights into the willingness of 
populations to utilize a proposed prevention or treatment strategy, as well as elucidate barriers and enablers 
of uptake. These findings can provide context to the acceptability of an intervention,12 inform health 
education efforts,13,14 and characterize provider opinions and preparedness.15 We conducted a multi-country 
cross-sectional study of HHCs of MDR TB index cases in diverse high TB burden settings to understand 
how HHCs’ TB-related knowledge, attitudes and practices (KAP) are associated with their willingness to 





The study was conducted from Oct/2015 to Apr/2016 at 16 clinical research sites in 8 countries: Botswana 
(1 site), Brazil (1), Haiti (1), India (2), Kenya (1), Peru (2), South Africa (7) and Thailand (1) in preparation 
for the Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis 
Patients (PHOENIx) trial being conducted by the AIDS Clinical Trials Group (ACTG, 
https://actgnetwork.org/) and International Maternal Pediatric Adolescent AIDS Clinical Trials Network 
(IMPAACT, http://impaactnetwork.org/). Information on local TB program activities related to contact 
tracing and TB preventive therapy was collected through key informant interviews (Table 4.1).  
 
Study participant eligibility criteria and recruitment: 
Pulmonary MDR TB index cases were eligible for enrollment if they met the following inclusion criteria: 
(1) documented rifampicin resistance by Xpert MTB/RIF, line probe assay or phenotypic drug-sensitivity 
testing; (2) MDR TB treatment initiation within 6 months of study enrollment, (3) ≥1 HHC, (4) permission 
for the study team to enumerate and screen HHCs, and (5) residing at a distance deemed by the site-level 
study team close enough for study conduct. HHCs were defined as: (1) any person currently living or having 
lived in the same dwelling unit or plot of land, (2) currently sharing or having shared the same housekeeping 
arrangements as the index case, and (3) reporting exposure within 6 months prior to the index case starting 
MDR TB treatment. A convenience sample of index cases was recruited and all their eligible adult and 
adolescent HHCs (≥13 years of age) without active TB were asked to complete a KAP questionnaire. 
 
Data collection and variables: 
A semi-structured KAP questionnaire was adapted for MDR TB from a recent World Health Organization 
(WHO) guide for tuberculosis KAP survey development.16 The survey was pilot tested among TB 
community health workers at one study site (India Site #2). The final questionnaire consisted of three 
sections with 40 total items: TB knowledge (signs, symptoms, mode of transmission, presence of a cure, 
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treatment – 12 questions), attitudes (fear, stigma, community support – 10 questions) and practices 
regarding TB (willingness to obtain prerequisite tests for LTBI treatment, take MDR TB preventive therapy 
and participate in a clinical trial – 18 questions). Additional HHC information obtained included: 
demographic, social, medical and household characteristics. All questionnaires were completed in-person 
by trained field staff or clinicians prior to participant education or counseling by anyone affiliated with the 
study.  
 
The primary outcome in this analysis was willingness to take a hypothetical newly developed MDR TB 
preventive therapy. Willingness to take this therapy even if it caused mild temporary side effects was 
analyzed as a secondary outcome. These outcome variables as well as HHC willingness to have a blood test 
(i.e. interferon gamma release assay), to provide a sputum sample, and to obtain a chest x-ray to determine 
if the HHC was a good candidate for preventive therapy were collected as categorical (yes, not sure, no) 
and dichotomized as yes vs. not sure or no for analysis.  
 
TB knowledge was analyzed as a binary variable, where appropriate knowledge was defined as correctly 
identifying all of the following: cough ≥3 weeks is a symptom of TB; TB is a curable disease; TB is 
transmitted via air when an infected person coughs or sneezes, and MDR TB cure is possible through 
directly observed therapy.17 ‘Incomplete’ knowledge was defined as not correctly identifying all four items 
above. Confidence in taking MDR TB preventive therapy was defined as HHCs feeling confident or very 
confident in being able to perform all five of the following (5-point likert scale): meeting with study staff 
monthly to take medications, coping with difficulties the medication may cause, taking all doses, continuing 
to take medications even if feeling healthy, and completing medications. The presence of TB-related 
symptoms was defined differently for HHCs <15 and ≥15 years of age. For adolescents or children (<15 
years), TB-related symptoms included any of the following at the time of interview: neck swelling, fever, 
night sweats, cough ≥10 days, poor weight gain, less playful, convulsion or decreased consciousness. For 
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adults (≥15 years), symptoms included any of the following in the past month: cough ≥10 days, fever, night 
sweats, unintentional weight loss or enlarged lymph nodes. 
 
Statistical analysis: 
The primary objective of this analysis was to evaluate the association between HHC-level KAP factors and 
willingness to take a newly developed preventive therapy. Among enrolled HHCs with complete KAP data, 
aggregate and site-level exploratory data analysis was conducted using summary statistics and scatter plots. 
Simple (adjusting only for research site) and multivariable marginal logistic models for willingness to take 
preventive therapy were fit using generalized estimating equations (GEE) with robust variance estimates to 
account for household-level clustering assuming an exchangeable within-household correlation structure.18 
Fixed effect dummy variables for research sites were included to adjust for variation between sites. 
Informed by a literature review and the Health Belief Model (Supplementary Figure 4.1),19 covariates of 
interest were selected prior to analysis from a larger set of variables available through the PHOENIx 
Feasibility Study.  
 
All HHCs at one site (Thailand) reported willingness to take preventive therapy. To allow model fit, the 
outcome status of one randomly selected HHC at this site was set to not willing. The sensitivity of model 
parameter estimates to this random outcome reassignment was examined. The potential confounding of 
HHC-level associations by corresponding household (HH)-level aggregate variables was also evaluated. 
Model diagnostics included examining the influence of individual HHCs and research sites on parameter 
estimates as well as residual plots.20 All analyses were conducted in Stata v13.1 (StataCorp, College Station, 
TX, USA) except for the creation of diverging stacked bar charts, which were created in R (v3.3.2) using 






Human research ethics approvals: 
Ethical approval was obtained from each research site’s local institutional review board. Written informed 
consent was obtained for all participating MDR TB index cases and their household contacts prior to study 




Across all sites, 328 adult pulmonary MDR TB index cases were screened during the recruitment period; 
20 declined screening or were ineligible. Three declined contact with HHCs, and 27 had no eligible, 
enrolled HHCs who also completed the KAP questionnaire.  
 
Characteristics of MDR/RR-TB index cases and their households: 
Among included index cases (n=278), the median time between MDR TB treatment initiation and study 
enrollment was 68 days [interquartile range (IQR) 29-125] with a majority also reporting a history of prior 
TB (53%). The median number of eligible, enumerated HHCs of all ages in these index case households 
was 4 (IQR 2-5) with 32% of households having ≥1 adolescent HHC (13 to <18 years of age), 31% ≥1 
HHC <5 years of age and 6% with ≥1 pregnant HHC. 
 
Characteristics of enrolled HHCs of MDR/RR-TB index cases: 
For the analysis of factors associated with willingness to take preventive therapy, complete KAP data were 
available for 743 adult and adolescent HHCs (99.7% of the 745 enrolled, and 79% of the 946 without active 
TB and eligible for the KAP study) from 278 MDR/RR-TB index case households (median 2 enrolled 
HHCs with complete KAP data per HH, IQR: 1-3) (Figure 4.1). The median number of MDR TB index 
cases and HHCs enrolled per site and included in this analysis was 14 (IQR 10–25) and 39 (IQR 22-70), 
respectively. Among HHCs participating in the KAP study, the median age was 33 years (IQR 22–49), 62% 
were women, 58% had a secondary school education or higher, and 46% were currently employed or in 
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school. In social history, 10% of HHCs reported prior TB treatment and 21% current smoking tobacco use. 
For alcohol use, 66 HHCs (9%) reported daily or almost daily alcohol use in the last year (n=58) or refused 
to answer the question (n=8 HHCs). Similarly, 60 reported drug use in the last year (n=57) or refused to 
answer (n=3) (Table 4.2). Participation in the KAP study was not associated with age, but females were 
more likely to participate than males (83% vs. 72%).  
 
MDR/RR-TB HHCs and their TB-related knowledge and attitudes: 
Appropriate MDR TB knowledge was demonstrated by 66% of enrolled HHCs with substantial site-level 
variation (Supplementary Figure 4.2), notably at India Site #1 (5%). Although 87% of all adult and 
adolescent HHCs participating in the KAP study (n=743) reported that TB transmission is airborne, 54% 
of these HHCs also stated that transmission can occur through sharing utensils, 40% by sharing clothes or 
towels, 24% by touching items in public places and 15% by handshakes. Among the 595 (74%) HHCs who 
stated that a cure for MDR TB exists, 94% responded that this cure was possible through directly observed 
therapy (DOT). These HHCs also reported that a cure was possible through means other than DOT: good 
nutrition (80%), praying or religious acts (18%), herbal remedies (11%), and rest without medication 
(7%).A majority of HHCs (64%) were concerned about being infected with MDR TB from their diagnosed 
household member, and 84% believed that someone could die from MDR TB without proper treatment. 
Regarding perceived stigma, 28% of HHCs reported that a person with TB is usually rejected by their 
community, and 34% stated that they would be uncomfortable telling family members or friends they were 
taking MDR TB preventive therapy (Table 4.2).  
 
Willingness of MDR/RR TB HHCs to take a newly developed MDR TB preventive therapy 
HHC willingness to take a newly developed MDR TB preventive therapy was high overall (79%) with 
observed site-level variation (site-level median 90%, IQR 84-95%; Figure 4.2). Willingness to take a 
preventive therapy with potential mild temporary side effects was lower (70% overall; site-level median 
80%, IQR 66-91%). Reported HHC willingness to complete prerequisite steps to determine preventive 
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therapy eligibility was also high overall: blood test (96%, IQR 88-98%), provide sputum sample (97%, IQR 
95-100%) and obtain chest x-ray (100%, IQR 97-100%). Notably at India Site #1, only 7% of HHCs 
reported willingness to take a newly developed preventive therapy (29% not willing, 64% not sure) with 
low percentages willing to have a prerequisite blood test (22%), provide a sputum sample (9%) or obtain a 
chest x-ray (9%). 
 
In the multivariable model for the primary outcome (Table 4.2), increased willingness to take preventive 
therapy was significantly associated with the following HHC characteristics: currently employed or in 
school [adjusted Odds Ratio (aOR) 1.82, 95% confidence interval (CI) 1.06, 3.12], appropriate TB-related 
knowledge (aOR 2.23, 95%CI 1.24, 4.03), confidence in taking preventive therapy (aOR 7.34, 95%CI 3.39, 
15.91), and being comfortable telling family or friends about taking preventive therapy (aOR 2.29, 95%CI 
1.28, 4.09). Decreased willingness was associated with any drug use in the past year (aOR 0.28, 95%CI 
0.10, 0.78) and marginally associated with prior treatment for TB (aOR 0.41, 95%CI 0.15, 1.13). In a 
multivariable model including the same set of covariates, the secondary outcome of willingness to take 
preventive therapy with side effects was significantly associated with increased HHC-level concern about 
being infected from the index case (aOR 2.02, 95%CI 1.30, 3.11) and confidence in taking preventive 
therapy (aOR 7.89, 95%CI 4.12, 14.08) as well as marginally associated with prior TB treatment (0.53, 
95%CI 0.26, 1.09). 
  
Site-level variation was observed in the unadjusted associations between willingness to take preventive 
therapy and covariates of interest (Supplementary Table 4.2); however, the direction of these associations 
was consistent for the most significant covariates identified through the multivariable model: appropriate 
TB-related knowledge, comfort telling family or friends about taking preventive therapy, confidence in 
taking preventive therapy, and substance use in the past year. After adjustment for all covariates included 
in the multivariable model, the predicted willingness of HHCs at India Site #1 remained significantly lower 
than all other sites on pairwise comparisons with Bonferroni correction. Potential confounding of observed 
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HHC-level associations by between-household effects was examined by creating HH-level summary means 
for all HHC-level covariates.22 Including all aggregate HH-level variables in the final multivariable model 
did not qualitatively change any HHC-level association except HHC education, which was not significant 
in either model. In sensitivity analyses, the direction and magnitude of HHC-level variable associations 
with willingness to take preventive therapy was robust to exclusion of India Site #1 and primary outcome 
reassignment of each of the 25 individual HHCs at the Thailand research site (Supplementary Figures 4.3 
and 4.4).  
 
Discussion: 
In this large multi-country study of HHCs of MDR TB index cases residing in diverse high TB burden 
regions, willingness to take a newly developed preventive therapy was high (79%) along with willingness 
to complete prerequisite steps to determine eligibility for treatment. These findings are similar to prior 
observational studies and case series from limited settings that have documented high levels of MDR TB 
preventive therapy initiation among contacts. In studies identified through recent systematic reviews on 
MDR TB preventive therapy,4,9,23 data on treatment initiation has been reported for eight generally small 
cohorts (median 30 contacts, IQR 22-36) (Supplementary Table 4.1). For these studies, treatment 
initiation, defined as taking any MDR TB preventive therapy for ≥2 weeks, was reported to be high overall 
(median 85.6%, IQR 71.2-93.4%); however, no data were available on factors associated with uptake.24-30 
Considerably more evidence exists for DS TB preventive therapy. In a recent meta-analysis of 25 cohorts, 
88% of individuals were estimated to have started preventive therapy if it was recommended, and factors 
associated with initiation, included: younger age, high perceived risk of TB and no prior LTBI treatment.31 
 
In the context of multiple ongoing clinical trials to identify effective MDR TB preventive therapy 
regimens,11 the present study provides evidence from diverse geographic settings for the potential high 
uptake of these therapies when implemented in the high risk population of household contacts. The 
identification of factors associated with increased willingness to take preventive therapy can inform 
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counseling efforts, generate hypotheses for more contextualized local studies of KAP factors, and identify 
populations where implementation of preventive therapy may be particularly effective or challenging. 
Appropriate TB-related knowledge, being comfortable speaking with family and friends about taking 
preventive therapy and most notably confidence in properly taking the regimen were all associated with 
increased willingness to start treatment. The marginal association between current HHC tobacco smoking 
and increased willingness to take MDR TB preventive therapy suggests a possible opportunity for increased 
preventive therapy uptake among a population at higher risk of both LTBI and active disease.32 Many of 
these identified factors have been previously identified to be associated with DS TB preventive therapy 
initiation or completion.31,33-34 Factors included in the present study’s KAP questionnaire were primarily 
patient-level, social and lifestyle;34 however, health system factors (e.g. clinic wait times, provider opinions 
on preventive therapy, and provider-patient communication) and therapy characteristics (e.g. duration, side 
effects) have also been demonstrated to be important predictors of treatment initiation and completion.31,33-
36 Observed associations may furthermore be confounded by unmeasured HHC- or HH-level variables.  
 
The decreased willingness of HHCs to take preventive therapy with mild side effects is also consistent with 
prior research, which has identified side effects as a primary reason for treatment discontinuation.26,30 
Although some studies have documented high completion rates of preventive therapy regimens among 
initiators,25,27-28 completion has been demonstrated to be one of the primary gaps in the LTBI cascade of 
care.31 Self-reported willingness to initiate treatment may not be a strong proxy for HHC completion of 
treatment or even future initiation due to social desirability bias or changes in beliefs, attitudes or 
circumstances over time.37,38 Additional limitations of this work include variable site-level sample sizes due 
to a constrained period of enrollment after the overall target of 300 index cases was met. As a result, the 
study sample is weighted toward sites starting enrollment earlier and with faster rates of recruitment (Figure 
4.2) as well as households with greater numbers of HHCs. Although this study may have lacked power to 
detect differences in associations among sites, identified associations were highly consistent across sites; 




In conclusion, the high percentage of HHCs of MDR/RR-TB index cases willing to take a newly developed 
MDR TB preventive therapy provides important evidence for the potential uptake of effective preventive 
therapy when implemented. Identified HHC-level variables associated with decreased willingness to take 
preventive therapy may inform education and counseling efforts to increase HHC confidence in and uptake 
of MDR TB preventive therapy. While the present research focused on willingness to take preventive 
therapy at the HHC-level, further research examining the site-specific context of TB-related KAP through 
qualitative or mixed methods studies offers promise in guiding the rollout of preventive therapy to reduce 
the burden of TB in these high-risk populations. 
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Table 4.1: Routine practices of TB Control Programs affiliated with participating clinical research sites 
 
 
*Follow-up with contacts of MDR TB patients: unknown duration 
∞Two sites in South Africa routinely provide three-drug therapy: fluoroquinolone + ethambutol + an additional medication 
Abbreviations: HHCs (household contacts); MDR TB (multidrug-resistant tuberculosis); INH (isoniazid); PZA (pyrazinamide) 
 
 89 
Table 4.2: Characteristics of 743 enrolled MDR TB household contacts from 278 index case households 
and factors associated with their willingness to take a newly developed MDR TB preventive therapy 
 
*Column and row percentages unless otherwise specified; confidence intervals not overlapping odds ratio null value are bolded 
Abbreviations: MDR TB (multidrug resistant tuberculosis); PT (preventive therapy); col (column); aOR (adjusted odds ratio); CI 
(confidence interval); p (p-value); IQR (interquartile range); ref (reference group); 12m (12 months); HH (household)  
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Figure 4.1: Eligibility, enrollment, and participation of 743 adult and adolescent household contacts from 
278 MDR/RR-TB index case households participating in the PHOENIx feasibility knowledge, attitudes 






Figure 4.2: Willingness of MDR/RR-TB household contacts to take newly developed MDR TB preventive 
therapy stratified by clinical research site (left panel). Number of enrolled MDR/RR-TB household contacts 





Supplementary Table 4.1: Prior studies on MDR TB preventive therapy reporting treatment initiation 
 
Abbreviations:  
- General: TB (tuberculosis); DR (drug-resistant); DS (drug-susceptible); PLHIV (person living with human 
immunodeficiency virus); LTBI (latent TB infection) 
- Eligibility criteria: TST (tuberculin skin test); mm (millimeter); CXR (chest x-ray); QGIT (QuantiFERON-TB Gold In-
Tube); IU (international units); CT (computed tomography); hr (hour); y (year) 
- Preventive therapy: m (months); LFX (levofloxacin); PZA (pyrazinamide); MFX (moxifloxacin); EMB (ethambutol); ETH 
(ethionamide); FQ (fluoroquinolone); INH (isoniazid); OFX (ofloxacin)
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Supplementary Figure 4.1: Conceptual framework for the relationship between KAP factors and 
willingness to take a newly developed MDR TB preventive therapy was informed by the Health Belief 
Model, which is grounded in social psychological theory 
 
In this conceptual framework, the likelihood of action (i.e., taking preventive therapy) is dependent upon 
four categories of factors: 1) an individual’s perception of the severity of TB and their susceptibility; 2) 
presence of cues to action, such as a prior history of TB; 3) an individual’s assessment of the benefits of 
and barriers to preventive therapy; and 4) modifying factors, including knowledge of TB, geographic 
location, social and demographic characteristics, as well as risk of TB. The causal relationships between 





Supplementary Figure 4.2: Correct number of responses to four TB knowledge questions among adult 
and adolescent HHCs of MDR/RR-TB index cases by clinical research site. Knowledge was defined as 
correctly identifying each of the following: 1) symptoms of TB: cough ≥3 weeks is a symptom of TB, 2) 
TB is a curable disease: yes (vs. no or not sure), 3) TB transmission: via air when an infected person coughs 
or sneezes, and 4) MDR TB cure: is possible through directly observed therapy. In the above graph, blue is 
the percent of HHCs at a clinical research site who identified the correct response to the above four 





Supplementary Figure 4.3: Sensitivity of final multivariable model (outcome: willingness to take a newly 
developed preventive therapy) parameter estimates to the exclusion of each research site. Labeling of each 
point estimate and 95%CI: full multivariable including all sites (red) 1: Botswana, 2: Brazil, 3: Haiti, 4: 
India Site #1 (blue), 5: India Site #2, 6: Kenya, 7: Peru Site #1, 8: Peru Site #2, 9: South Africa Site #1, 10: 
South Africa Site #2, 11: South Africa Site #3, 12: South Africa Site #4, 13: South Africa Site #5, 14: South 




Supplementary Figure 4.4: Sensitivity of final multivariable model (outcome: willingness to take 
preventive therapy) parameter estimates to outcome reassignment of single HHC from willing to take 
preventive therapy to not willing to take preventive therapy. Outcome reassignment was necessary to allow 
model fit for HHC data from the Thailand clinical research site where all enrolled HHCs reported 




Supplementary Table 4.2: Unadjusted site-level associations between willingness to take preventive therapy and HHC-level covariates 
 
*Simple logistic model fit using GEE and robust SE did not converge; point estimate of OR is from simple logistic model fit using robust SE (Huber and White sandwich estimator) 
Abbreviations: HHCs (household contacts); PT (preventive therapy); TB (tuberculosis); MDR (multidrug-resistant); Sx (symptom); IC (index case) 
EPPO = exposure perfectly predicts outcome 
NV0 = no variation in exposure variable (all HHCs opposite exposure status as listed at top of table, i.e. exposure status = 0) 
NV1 or NV2 = no variation in exposure variable (all HHCs with exposure status as listed at top of table, i.e. exposure status = 1 (NV1) or 2 (NV2)) 
P0 (## / ##) = no variation in outcome status conditional on exposure; all HHCs with exposure variable = 0 had same outcome. (## / ##) = number of HHCs with exposure status = 0 out of total number   
      of HHCs at site 
P1 (## / ##) = no variation in outcome status conditional on exposure; all HHCs with exposure variable = 1 had same outcome. (## / ##) = number of HHCs with exposure status = 1 out  of total number  
      of HHCs at site 
%, % = percentage of HHCs with exposure status = 0 who were willing to take preventive therapy // percentage of HHCs with exposure status = 1 who were willing to take preventive therapy 
Font color-code:  
      Red font = percentage of HHCs with exposure = 0 that were willing to take preventive therapy was greater than percentage HHCs with exposure = 1 that were willing 
      Blue font = percentage of HHCs with exposure = 1 that were willing to take preventive therapy was greater than percentage HHC s with exposure = 0 that were willing  
Background color-coding: odds ratio 
      Exposure status = 1 associated with lower unadjusted odds of willingness to take preventive therapy: light red: OR <1.00 and >=0.667; medium red:  OR <0.667 and >=0.4; dark red: OR <0.4 
      Exposure status = 1 associated with higher unadjusted odds of willingness to take preventive therapy: Light blue: OR = >1.00 and <=1.50; medium blue: OR >1.50 and <=2.50; dark blue: OR >2.50 
Background color-coding: p values for multivariable model: green: p <0.05; yellow: p <1.00 and >0.05
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The previous chapters highlight the importance of understanding both traditional and patient-reported MDR 
TB treatment outcomes as well as associated factors. This understanding at both centralized and local levels 
can provide crucial context about TB program functioning and inform the development or evaluation of 
patient support programs. The strong associations of anemia and malnutrition, manifestations of severe TB 
disease, with mortality suggest potential needs for earlier MDR TB diagnosis and more aggressive treatment 
in efforts to improve outcomes. Indeed, the finding that mortality rates were significantly lower for MDR 
TB patients registered in 2015 compared to 2016 is a positive indicator of progress. The higher hazard of 
loss follow-up as well as impaired environmental quality of life for patients with a history of alcohol use 
was highly consistent with prior research and points to the need of moving from descriptive studies to 
piloting novel methods of alcohol treatment interventions or scaling up known effective ones. Ongoing 
efforts within RNTCP to conduct effective operational research in order to guide the implementation of 
novel diagnostic, treatment, and patient support strategies will continue to improve MDR TB care in India. 
 
In general, leveraging existing and largely standardized programmatic data offers promise to both inform 
local practices as well as share developed research tools and lessons learned with other interested sites. The 
cultivation of strong local collaborations can provide important context to data, help focus research 
questions on topics meaningful to the program and facilitate the rapid translation of substantive research 
findings into practice. The utilization of multiple imputation to address missing data challenges as well as 
competing events approaches can enhance the strength of analyses from programmatic data with near 
ubiquitous challenges of data quality.  
 
Lastly, the incorporation of patient-reported outcomes, such as quality of life, depressive symptoms, 
rigorously collected adverse drug events or TB-related stigma, into routine practice will be important for 
the future evaluation of activities and also provide key data for TB programs to be increasingly responsive 
to patient needs. Achieving the 2015 WHO End TB Strategy and the recent Government of India target of 
TB elimination by 2025 will require substantial efforts and funding to continue to improve MDR TB 
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care. Critical to meeting these targets is action based on a more systematic and granular understanding of 
the extent and severity of TB patient needs and the barriers to treatment retention.
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